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ABSTRACT 
Alessandra Bassalobre Garcia Reeves: Antimicrobial Stewardship Programs: Implications 
for Resistance Rates & Quality of Care in Hospitals 
(Under the direction Morris Weinberger) 
 
Each year, two million Americans acquire serious infections caused by bacteria that 
are resistant to antibiotics resulting in significant morbidity, mortality, health care utilization 
and costs. Despite the recent passage of an antimicrobial stewardship programs (ASP) 
mandate in California and the Centers for Disease Control and Prevention (CDC) guidelines 
for a minimum standard ASP in hospitals, literature on the impact of ASPs on antimicrobial 
resistance (AMR) rates in hospitals is sparse. 
The long-term goal of this study is to provide reliable evidence to influence policies 
and practices to reduce AMR and improve quality and clinical outcomes in hospitals. The 
overall objective of this study was to investigate the impact of ASP adoption, including the 
effect of a mandate in California and compliance with the CDC’s 7 core elements on 
methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile (C. diff) in 
acute care hospitals. Then, we investigated their impact on selected quality and clinical 
outcomes. 
In paper 1, we estimated the impact of passing an ASP mandate in California on 
hospital on MRSA and C. diff rates using 2013-2017 hospital-level data and a difference-in-
difference with hospital fixed effects (FE) design. We found that, compared to hospitals in 
other states, California hospitals had significant (p<0.05) increases of 23%, 30%, and 20% in 
their MRSA SIR in 2015, 2016 and 2017, respectively. We also observed a 20% (p<0.001) 
decrease in their C. diff SIR in 2017. 
Paper 2 examined the effect of statewide adoption of the CDC’s ASP 7 core 
components on MRSA and C. diff rates using 2014-2016 data to estimate a state FE model. 
We found that the percentage of hospitals meeting the CDC’s 7 core elements for ASP 
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between 2014 and 2016 increased in all states. A one percentage point increase in ASP 
compliance was associated with a 0.3% decrease (p<0.01) in C. diff infections in 2016 
relative to 2014. We did not find an effect on MRSA infections. 
In paper 3, we measured the association between rates of MRSA/C. diff and quality 
and clinical outcomes in US acute care hospitals using 2013-2017 hospital-level data and a 
hospital FE model. We found no association of MRSA or C. diff with 30-day readmissions, 
length of stay, 30-day mortality and intensive care unit days. 
In summary, this study examined the various effects of an ASP state mandate and 
adoption of the CDC’s 7 core elements, as well as the relationship between AMR and quality 
and clinical outcomes in hospitals. Our findings help fill important knowledge gaps and can 
assist policymakers and healthcare administrators make informed decisions on the 
regulation and implementation of ASPs. Future studies should seek data on hospital-level 
implementation of specific components of ASP and other resistant bacteria, neither of which 
is currently available. 
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CHAPTER 1. INTRODUCTION 
Background 
Each year, as many as 2 million Americans will acquire serious infections caused by 
bacteria that are resistant to one or more antibiotics resulting in 23,000 deaths, $20 billion in 
direct healthcare costs, and $35 billion in overall societal costs1. A major modifiable driver of 
antimicrobial resistance (AMR) is antibiotic prescribing and utilization practices2: up to 50% 
of antibiotic prescriptions are neither necessary nor appropriate in outpatient and inpatient 
settings1,3. 
Antimicrobial stewardship programs (ASPs) are universally recognized as essential 
tools in infection control throughout the healthcare system4. ASPs are associated with 
shorter hospitalizations and decreased antimicrobial consumption5. Studies on the 
effectiveness of ASPs are relatively recent and use varied assessment perspectives6,7. 
However, the impact of ASPs on actual AMR rates in hospitals is uncertain5 or not explored. 
My long-term goal is to provide reliable evidence to influence policies and practices 
to reduce the rates and associated consequences of AMR in hospitals. My overall study 
objective is to investigate the impact of an ASP mandate in California and distinguish 
standards of ASPs (CDC’s 7 Core Elements) that may have a greater impact on reducing 
AMR rates in hospitals and, consequently, improving quality metrics nationwide. My central 
hypothesis is that hospitals with more restrictive ASPs (e.g., CA hospitals after the ASP 
mandate or those hospitals meeting the CDC’s 7 Core Elements) will have lower AMR rates 
and higher quality care. This hypothesis is based on the meta-analysis by Karanika et al.5, 
which found an overall reduction in AMR cases, general antimicrobial costs and length of 




I test my central hypothesis by pursuing the following specific aims: 
Aim 1: Estimate the impact of passing an ASP mandate in California on hospital 
methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff) rates. 
My hypothesis is that after July 2015, MRSA and C. diff rates dropped significantly in 
California compared to hospitals in other states. I use 2013-2017 HospitalCompare data and 
a difference-in-difference with hospital fixed effects (FE) design to estimate the effect of 
passing this bill. 
Aim 2: Examine the association between statewide adoption of the CDC’s 7 Core 
Elements of ASP and hospital MRSA and C. diff rates. My hypothesis is that states with a 
higher percentage of compliance to the CDC’s 7 core elements for ASPs will have 
significantly lower MRSA and C. diff rates. States’ percentage of adoption of the 7 core 
components over time (2014-2016) were retrieved from the CDC’s Patient Safety Atlas 
dataset. I use 2014-2016 HospitalCompare data and fixed effects (FE) regressions to 
estimate this association. 
Aim 3: Measure the association of MRSA and C. diff rates with quality and clinical 
outcomes in hospitals nationwide. My hypothesis is that higher rates of MRSA and C. diff in 
acute care hospitals are related to higher rates of 30-day hospital readmissions, 30-day 
mortality, longer length of hospital stay and more intensive care unit (ICU) days in US 
hospitals. To test these hypotheses, I use a hospital FE model and 2013-2017 
HospitalCompare data. 
This study will provide a nationwide overview of the effect of implementing ASP 
programs (statewide mandate, CDC core components) on AMR rates, as well as the 
relationship between AMR and quality and clinical outcomes in hospitals. Our findings can 
provide healthcare administrators and policy makers with evidence to support a mandate for 
minimum standard ASPs across the country. If effective, these strategies may help prevent 
the emergence of AMR, reduce the morbidity, mortality and health care costs associated 
with AMR infections in hospitals. 
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Significance 
ASPs in hospitals shape prescribing practices and are intended to reduce the 
emergence of AMR. In hospital settings, ~40% of inpatients will receive antimicrobial agents 
as part of their treatment8; a large share of those prescriptions is neither necessary nor 
appropriate1. These sub-optimal practices are, at least in part, responsible for the 
emergence of AMR. Strategies to promote careful, discriminatory use of antimicrobial drugs 
can reduce AMR9. ASPs are universally recognized as essential tools in infection control 
throughout the healthcare system4. For example, formulary restrictions (or preauthorization), 
the most common type of ASP, can be especially impactful if enforced5 because they directly 
address prescribing practices, preventing overuse and misuse of antimicrobials10–12.  
The assessment of ASPs is incipient and has not been standardized across studies 
in different states. Virginia and Kansas, for example, were assessed for their ASPs with 
different criteria7,13, and a nationwide survey found that only 39% of acute care hospitals 
implemented CDC’s 7 core elements of ASPs6. California is the only state that currently has 
an ASP mandate with specific requirements for hospitals. One study investigated how 
implementation of hospital ASPs changed after the passage of the mandate in California; 
however, it did not address its impact on hospital resistance rates14. 
Empirical evidence about the effects of different ASPs on AMR rates in hospitals is 
limited and not reliable. Although many studies examine ASPs in hospitals, most analyze 
their impact on prescribing practices and antibiotics use11,12,15–17 rather than directly on AMR 
rates. The two US studies that included AMR rates as an outcome18,19 have important 
methodological limitations. One did not address selection bias and the 1-year follow up 
period might have been too short to detect changes in the resistance rates18. In the other 
study, confounders and selection bias were not addressed at all19. One international study 
found lower AMR rates after implementation of ASP, although the study was susceptible to 
measurement error20. In this study, I will employ estimation methods that address ASP 
selection bias to examine actual AMR rates (MRSA and C. diff). 
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There is uncertainty around ASPs that are truly effective and the extent to which they 
affect AMR and quality metrics. A recent meta-analysis found that formulary restriction ASPs 
are associated with shorter hospitalizations and decreased general and restricted (broad 
spectrum) antimicrobial consumption and costs. However, results from the included studies 
were mixed5, which is probably because the type and characteristics of ASPs were not 
addressed in detail. Whether or not ASPs meet the CDC’s 7 core components were not 
addressed in those studies. 
In summary, this research is significant because: 
1) It will shed light on a major, persistent patient safety and healthcare quality 
problem within hospitals. Although preventable, AMR remains a prevalent, costly and deadly 
problem at the intersection of healthcare quality and safety. AMR also threatens global 
health security because of its potential to spread across patients, hospitals and countries1,21. 
This research seeks to unpack the effectiveness of an ASP mandate and the 7 core 
elements in preventing the emergence of AMR. 
2) It addresses important gaps in the literature by providing a picture of how AMR 
may affect quality and clinical outcomes. A better evidence-based understanding of this 
relationship is important because it will help healthcare settings improve efficiency of their 
services and patient outcomes by preventing adverse events and the spread of resistant 
strain bacteria. 
3) Understanding the impact of ASPs on AMR rates may have significant policy 
implications. The knowledge generated from this study can assist policymakers and 
healthcare administrators make informed decisions on implementing effective ASPs. 
Because most states do not have a mandate for ASPs, findings from this study could provide 
evidence for a minimum standard ASP to be required by state mandates in the future. 
Innovation 
AMR is a major public health problem lying at the intersection of healthcare quality 
and global health security that has not been successfully addressed1,21. AMR is not a novel 
problem, but it has gained more attention lately because of a rapid increase in resistance 
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rates, a small number of newly-developed antimicrobial agents22, and its potential to spread 
across patients, hospitals and countries21. Most research to date has collected non-
standardized information on ASP6,7,13 and used prescribing practices, rather than AMR rates, 
as the outcome. One major challenge to previous research is that information on ASPs are 
not easily found in publicly available datasets. 
This study is innovative because it represents a departure from the status quo by 
shifting focus to the effects of ASP as defined by the CDC on actual rates of AMR. We 
combined data from different sources to test hypotheses about the relationship between 
ASP and AMR using MRSA and C. diff infections as models. In our study, we combined 
state-level rates of compliance with the CDC standard for hospital ASPs with publicly 
available hospital-level MRSA and C. diff rates. This unique dataset allowed us to examine 
the association between CDC-standard ASPs and AMR rates. Because there are likely 
unmeasured hospital characteristics confounding this relationship, we will use a time and 
hospital fixed effects approach for more consistent estimates. 
Moreover, we investigated the effect of California’s mandate to adopt and implement 
a minimum-standard ASP in hospitals. Ours will be the first policy analysis that estimates the 
effect of such mandate in the real world. This study will not only generate new knowledge on 
the topic but also serve as a model for future research in the area. I will also examine the 
relationship between AMR rates and selected quality and clinical outcomes across hospitals 
nationwide, which offers greater external validity compared with previous studies that used 
single hospital settings.  
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CHAPTER 2. OVERALL METHODS 
Conceptual Framework 
The conceptual model for this study is adapted from Donabedian23, which uses three 
categories of healthcare quality: structure (physical structure, financing model, equipment 
and staff), process (interactions and process through which care is delivered to patients) and 
outcomes (effects on quality metrics and health outcomes of patients)23. The ASP types, 
teams and characteristics (e.g., whether they meet CDC’s 7 core components of ASP) are 
structural characteristics of a hospital that have the potential to directly shape antimicrobial 
prescribing (process) and, in turn, AMR rates through antimicrobial selective pressure 
(outcomes). AMR rates will affect other quality outcomes as a result (Figure 2.1). The box 
with confounders lists potential factors that could impact both ASP (main explanatory 
variable) and AMR rates (main outcome). 
Antimicrobial selective pressure is the main driver of AMR. Any bacteria can develop 
resistance through continuous exposure to routinely used antibiotics. This continuous 
exposure is what defines selective pressure and causes bacterial genome to rapidly evolve 
through genomic mutations, resulting in resistant strains24. 
Approach 
Aim 1: Estimate the impact of passing an ASP mandate in California on hospital MRSA and 
C. diff rates 
Hypothesis: After July 1, 2015 (passage of California SB 1311), MRSA and C. diff 
rates dropped significantly in California compared to other states. We used a difference-in-
difference with hospital FE model to estimate the effect of passing this bill. 
Natural experiment: California’s Senate Bill 1311, which was approved on September 
29, 2014, required that, by July 1 2015, all acute care hospitals in the state to: (1) adopt and 
implement an ASP in accordance with federal and professional guidelines that includes the 
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monitoring and evaluation of the judicious use of antimicrobials; (2) form a physician-lead 
multidisciplinary antimicrobial stewardship committee; (3) appoint to that committee a 
physician or pharmacist who has expertise in antimicrobial stewardship through prior training 
or participation in continued education programs; and (4) report ASP activities to appropriate 
hospital committees leading quality improvement activities25. After the passage of the SB 
1311, the percentage of hospitals in California which met CDC’s 7 core elements for ASPs26 
increased 16.6%: from 59.3% in 2014 to 69.2% in 201514. 
Data sources: We used 2013-2017 hospital-level data from the Centers for Medicare 
& Medicaid Services’ (CMS) HospitalCompare, Provider of Service File and Medicare Cost 
Reports files. MRSA and C. diff are the only rates that are publicly available. While an ideal 
outcome measure would be the combined resistance rates of all relevant microorganisms, 
MRSA and C. diff are still reasonable proxies of resistance in hospitals. 
Measures: The operational definition of each variable is presented, including the 
standardized infection ratio (SIR) for MRSA and C. diff27, are presented in Table 2.1. SIRs 
account for differences between hospitals (e.g., hospital’s patient case mix, hospital size, 
medical school affiliation). SIRs are defined as the ratio between number of infections 
detected by laboratorial tests and the number of infections predicted for a hospital with 
certain characteristics. 
Research design: We used a difference-in-difference with hospital FE design to 
estimate the effect of the passage of an ASP mandate in California on MRSA and C. diff 
SIR. Since California was the only state in the US to pass a mandate with specific 
requirements, we included all the other states in the comparison group. We used time FE to 
control for time trends. The estimating equation is illustrated below. We used 2013 as the 
reference year. 
Equation 1: 𝑀𝑅𝑆𝐴/𝐶. 𝑑𝑖𝑓𝑓_𝑆𝐼𝑅ℎ𝑠𝑡 = 𝛽0 + 𝛽1 𝐶𝑎𝑙𝑖𝑓𝑜𝑟𝑛𝑖𝑎𝑠 + 𝛽22014 +  𝛽32015 + 𝛽42016 +
 𝛽52017 + 𝛽6𝐶𝑎𝑙𝑖𝑓𝑜𝑟𝑛𝑖𝑎𝑠 ∗ 2014 + 𝛽7𝐶𝑎𝑙𝑖𝑓𝑜𝑟𝑛𝑖𝑎𝑠 ∗ 2015 + 𝛽8𝐶𝑎𝑙𝑖𝑓𝑜𝑟𝑛𝑖𝑎𝑠 ∗
2016 +   𝛽9𝐶𝑎𝑙𝑖𝑓𝑜𝑟𝑛𝑖𝑎𝑠 ∗ 2017 +  𝛽10 𝑋ℎ𝑡 + 𝜀ℎ𝑠𝑡 
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Where X represents a vector of time-variant covariates, h is an index for hospital, s is an 
index for state and t is the time period. Variables are defined in Table 2.1. 
Power calculations & sample size: From the few studies in the field, one found an 8 
percentage point decrease in the rate of MRSA over the course of 4 years (52% vs 44%) 
after the implementation of a preauthorization policy19; another study found a 9.9 percentage 
point decrease in the rate of meropenem-resistant P. aeruginosa during the 6 years (13.7% 
vs 3.8%) after implementing a computerized preauthorization and a prospective audit 
policy20. For our power analysis, we used the proportions and effect size from the first case 
with a 95% significance level and 80% power. Based on these parameters, a sample size of 
636 hospitals would be required in each group to detect an 8 percentage point difference. 
Aim 2: Examine the association between statewide adoption of the CDC’s 7 Core Elements 
of ASP and MRSA and C. diff rates in US states 
Hypothesis: States with a higher percentage of compliance to the CDC’s 7 core 
elements for ASPs will have significantly lower MRSA and C. diff rates. We tested this 
hypothesis by estimating a state and time FE model. 
Justification & feasibility: The study of ASPs has not been consistently addressed or 
emphasized. However, the CDC has recently released guidelines for a minimum standard 
ASP, which includes 7 core components to support optimal antibiotic use: leadership 
commitment, accountability, drug expertise, action (implement at least one recommended 
action), tracking, reporting and education26. Moreover, previous studies have examined the 
impact of ASPs on antimicrobial usage11,12,15–17 rather than AMR rates. Hospital adoption of 
ASPs is relevant because of the widespread use of antimicrobial agents in inpatient 
services8, which makes them more susceptible to the emergence of resistant strains. 
Data sources: Hospital-level measures of ASP are not publicly available. We merged 
different publicly available 2014-2016 data from HospitalCompare, Provider of Service and 
Medicare Cost Reports files. The state percentage of hospital adoption of the ASP 7 core 
components over time was retrieved from the CDC’s Patient Safety Atlas website. The ASP 
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data from the Patient Safety Atlas website refers to acute care hospitals nationwide, 
collected through the CDC’s National Healthcare Safety Network (NHSN). 
Measures: The outcomes in this aim are the same as in aim 1. The main explanatory 
variable is ASP, which is defined as the percentage of hospitals that meet the CDC’s 7 core 
components for ASPs26 in a given state. Other time-variant control variables are listed in 
Table 2.1. 
Research design: To account for time-invariant unmeasured confounders (Figure 
2.1), we used a state and time FE estimation model. Our main regressor was the percentage 
of hospitals that meet the CDC’s 7 core components for ASP in a given state over time 
(2014-2016). We estimated the association of this measure with two outcome variables: 
MRSA and C. diff SIR. We controlled for the time-variant characteristics listed in Table 2.1. 
We used Hausman tests to confirm model specification. 
Equation 2: 𝑀𝑅𝑆𝐴/𝐶. 𝑑𝑖𝑓𝑓_𝑆𝐼𝑅𝑠𝑡 = 𝛽0 + 𝛽1 𝑃𝑐𝑡𝐶𝑜𝑚𝑝𝑙𝑖𝑎𝑛𝑐𝑒𝑠𝑡 + 𝛽2 𝑆𝑡𝑎𝑡𝑒𝑠 + 𝛽3 𝑌𝑒𝑎𝑟𝑡 +
𝛽4 𝑋𝑠𝑡 + 𝜀𝑠𝑡 
Where X represents a vector of time-variant covariates, s is an index for state and t is the 
time period (variables are defined in Table 2.1). 
Aim 3: Measure the association of MRSA and C. diff rates with quality and clinical outcomes 
in hospitals nationwide 
Hypothesis: Higher rates of MRSA and C. diff in acute care hospitals are related to 
higher rates of 30-day hospital readmissions, 30-day mortality, longer length of stays, and 
more intensive care unit (ICU) days in US hospitals. We used hospital FE estimation 
methods to understand this association. 
Justification & feasibility: This aim addresses the need to understand the impact of 
AMR on quality and clinical outcomes which may provide the basis for decisions by health 
services providers, administrators and policy makers to improve care. These outcomes have 
been studied separately in various studies5,12,15,16,18–20; however, results were mixed, 
selection bias was poorly addressed and some were not clearly described. Moreover, 
several studies used a single setting for the study. We analyze the relationship between 
 10 
AMR rates and the selected outcomes across hospitals nationwide; therefore, results will be 
generalizable nationally. 
Data sources: We used 2013-2017 data from HospitalCompare, Provider of Service 
and Medicare Cost Reports files. The outcome variables were 30-day readmissions, length 
of stay, 30-day mortality and ICU days. Key explanatory variables were MRSA and C. diff 
SIR. Variables are defined in Table 2.1. The sample represents acute care hospitals 
nationwide which provide health services to Medicare beneficiaries. 
Research design: For each outcome, we estimated hospital and time FE models to 
control for time-invariant hospital characteristics that could confound the relationship 
between resistant strains and the outcomes of interest. We used clustered standard errors 
and weighted the regressions by hospital size. We used Hausman tests to confirm model 
specification. 
Equation 3: 𝑄𝑢𝑎𝑙𝑖𝑡𝑦/𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙_𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑠ℎ𝑡 = 𝛽0 + 𝛽1 𝑀𝑅𝑆𝐴/𝐶. 𝑑𝑖𝑓𝑓_𝑆𝐼𝑅ℎ𝑡 + 𝛽2 𝐻𝑜𝑠𝑝ℎ +
 𝛽3 𝑌𝑒𝑎𝑟𝑡 + 𝛽4 𝑋ℎ𝑡 + 𝜀ℎ𝑡 
Where X represents a vector of time-variant covariates, h is an index for hospital and t is the 
time period. 
Power calculations & sample size: One study28 observed an increased hazard of 
readmission (HR, 1.40; 95% CI, 1.33–1.46) for patients with a positive clinical culture for 
MRSA, Vancomycin-resistant Enterococcus (VRE) or C. diff. The 30-day readmission rate 
was 15% for patients with negative assay for those microorganisms and 25% for patients 
with a positive assay28. Therefore, we will use a 10% effect size, as well as 95% significance 
level and 80% statistical power for the power analysis. Based on these parameters, we will 
need at least 540 hospitals in total. 
Sample 
The flow chart in Figure 2.2 shows the hospital sample selected for the three aims. 
We included all CMS-certified hospitals in HospitalCompare from 2013-2017 and excluded 
VA hospitals (different data collection period), children’s hospitals (different case mix/hospital 
epidemiology), and critical access hospitals. The latter are required to report infection data 
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only in some states and most do not have the minimum number of infections required to 
calculate SIR. We also excluded hospitals outside of the US (Figure 2.2). 
Ethical Procedures 
This proposal does not qualify as human subjects research as defined by federal 
regulations (45 CFR 46.102(f)). All datasets used in this research were publicly available. 
The datasets contain hospital names, which were de-identified, but no individual/personal 
information. Since this research does not involve interaction with any individual/hospital and 
hospital data were already publicly available, there is no risk of inadvertent disclosure. This 
study was submitted to the Institutional Review Board (IRB) at the University of North 
Carolina at Chapel Hill and did not require IRB approval since it does not constitute human 
subjects research (study # 18-3311). 
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Figures & Tables 











Table 2.1 Data source and variables description for aims 1-3, 2013-2017 
Variable Description Source/Aim 
Outcomes & Key Explanatory Variables 
MRSAa SIRb MRSA standardized infection ratio: # observed MRSA 
bacteremia (laboratory-identified) divided by predicted # 
MRSA in the hospital. MRSA predicted events are 
calculated based on admission prevalence rate of 
MRSA infections, average length of stay, medical school 
affiliation, type of hospital, number of ICU beds, MRSA 




Outcome in aims 1 & 
2, explanatory 
variable in aim 3 
C. diffc SIR C. diff standardized infection ratio: # observed C. diff 
(laboratory-identified) divided by predicted # C. diff in 
the hospital. C. diff predicted events are calculated 
using type of laboratory test used to identify C. diff 
infection, whether the hospital has emergency 
departments and/or observation units that collect stool 
specimens for C. diff testing, facility bed size, number of 
ICU beds, medical school affiliation, admission 
prevalence rate of C. diff infections, and type of hospital 
Hospital Compare 
 
Outcome in aims 1 & 
2, explanatory 




% of hospitals that meet the CDC’s 7 core components 
for ASPs within a given state 




in aim 1 
California Dichotomous variable for whether the state is California 








% patients re-admitted to the hospital within 30 days of 
discharge. Includes Medicare beneficiaries only and is 
adjusted for patient characteristics. Data collected 
annualy from July to June. 
HospitalCompare 
 
Outcome in aim 3 
30-day Mortality 
Rate 
Death rate within 30 days of hospital admission for 
patients with selected diagnoses (weighted average of 
30-day mortality for chronic obstructive pulmonary 
disease, heart attack, heart failure, pneumonia and 
stroke). Includes Medicare beneficiaries only and is 
adjusted for patient characteristics. Three-year moving 
average, from July to June (e.g.: 2017 mortality refers to 
data from July 2014 to June 2017). 
HospitalCompare 
 
Outcome in aim 3 
Length of stay Mean length of inpatient stay in days Medicare Cost 
Reports 
 
Outcome in aim 3 
ICUe Days Number of inpatient days spent in the ICU Medicare Cost 
Reports 
 
Outcome in aim 3 
Time-Invariant Variables (not included in the models) 
Hospital 
ownership 
Categorical variable for public, private for-profit and 
private not-for-profit (referent category) 
Hospital Compare 
Rural Dichotomous variable for whether the hospital is in a 
rural area (=1; 0 otherwise) according to their Core 
Based Statistical Area (CBSA) code 




Dichotomous variable for whether the hospital provides 
emergency services (=1; 0 otherwise) 
Hospital Compare 
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Variable Description Source/Aim 
ICU Services Dichotomous variable for whether the hospital provides 
intensive care services (=1; 0 otherwise) 
CMS Provider of 
Service File 
Time-Variant Control Variables 
Teaching 
hospital 
Dichotomous variable for whether the hospital is 
affiliated with a medical school (=1; 0 otherwise) 
CMSd Provider of 
Service File 
 






Number of times hospital has undergone a change in 
ownership. Categorical variable for “No changes” (=1), 
“One time” (=2), “Two or more” (=3) changes in 
ownership within a given year 
CMS Provider of 
Service File 
 





Dichotomous variable for whether the hospital is 
accredited by a CMS-approved accreditation 
organization (=1; 0 otherwise). Quality accreditation 
organizations include The Joint Commission (most of 
accredited hospitals), American Osteopathic Association 
Healthcare Facilities Accreditation Program, Det Norske 
Veritas Germanischer Lloyd, and Center for 
Improvement in Healthcare Quality 






Dichotomous variable for whether the hospital is in 
compliance with Medicare Conditions of Participation 
(CoP) for all services, areas and locations covered by 
the hospital's provider agreement under its CMS 
Certification Number (=1; 0 otherwise) 





Composite measure of rates of pressure ulcer, 
iatrogenic pneumothorax, in-hospital fall with hip 
fracture, perioperative hemorrhage or hematoma, 
postoperative acute kidney injury, postoperative 
respiratory failure, perioperative pulmonary embolism 
(PE) or deep vein thrombosis (DVT), postoperative 
sepsis, postoperative wound dehiscence and 
unrecognized abdominopelvic accidental 
puncture/laceration. Includes Medicare beneficiaries 
only and is adjusted for patient characteristics. Two-year 
moving average, from July to June (e.g.: 2017 refers to 
data from July 2015 to June 2017). 
Hospital Compare 
 






% patients re-admitted to the hospital within 30 days of 
discharge. Includes Medicare beneficiaries only and is 
adjusted for patient characteristics. Data collected yearly 
from July to June. 
Hospital Compare 
 
a methicillin-resistant Staphylococcus aureus 
b Standardized infection ratio 
c Clostridium difficile 
d Antimicrobial stewardship program 
e Intensive Care Unit 
f Centers for Medicare and Medicaid Services 
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CHAPTER 3. IMPACT OF CALIFORNIA’S MANDATE FOR ANTIMICROBIAL 
STEWARDSHIP PROGRAMS ON RATES OF METHICILLIN-RESISTANT 
STAPHYLOCOCCUS AUREUS AND CLOSTRIDIOIDES DIFFICILE IN ACUTE CARE 
HOSPITALS 
Overview 
Objective: Estimate the impact of California’s Antimicrobial Stewardship Program 
(ASP) mandate on methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides 
difficile (C. diff) rates in acute care hospitals. Data Sources: 2013-2017 data from the 
Centers for Medicare & Medicaid Services’ (CMS) HospitalCompare, Provider of Service File 
and Medicare Cost Reports. Study Design: Difference-in-difference model with hospital 
fixed effects to compare CA with all other states before and after the ASP mandate. 
Outcomes: standardized infection ratio (SIR) for MRSA and C. diff. Time-variant covariates: 
medical school affiliation, bed count, quality accreditation, number of changes in ownership, 
compliance with CMS requirements, % intensive care unit beds, average length of stay, 
patient safety index, and 30-day readmissions rate. Principal Findings: In 2013, CA 
hospitals had an average MRSA SIR of 0.79 versus 0.94 in other states, and an average C. 
diff SIR of 1.01 versus 0.77 in other states. CA hospitals had increases (p<0.05) of 23%, 
30%, and 20% in their MRSA SIR in 2015, 2016 and 2017, respectively. CA hospitals were 
associated with a 20% (p<0.001) decrease in their C. diff SIR only in 2017 compared to 
other states. Conclusions: The mandate was associated with a decrease in C. diff 
infections and an increase in MRSA SIR in California versus all other states. 
Key words: antimicrobial resistance, antimicrobial stewardship programs, patient safety, 




While antibiotics were considered life-savers in the 1940s, the widespread misuse of 
antimicrobials has diminished their effectiveness, representing a rapidly-growing threat to 
public health29. Each year, as many as 2 million Americans will acquire serious infections 
caused by bacteria resistant to one or more antibiotics resulting in 23,000 deaths, $20 billion 
in direct healthcare costs, and $35 billion in overall societal costs1. 
The problem is not confined to the United States. The World Health Organization 
considers antimicrobial resistance (AMR) an emerging global threat30,31. The United Nations 
General Assembly launched a global effort to tackle AMR in 2016, and the European 
Commission, World Health Organization, G-7 and G-20 countries recently launched an 
antimicrobial stewardship action plan to address this issue of “extraordinary gravity”32,33.The 
problem has gained unprecedented political attention because antimicrobial consumption 
and the number of AMR infections are rapidly increasing in both developed and developing 
countries, where consumption increased 75% from 2000-201529,34. 
Antibiotic prescribing and utilization practices are major modifiable drivers of AMR2, 
with up to 50% of US antibiotic prescriptions being neither necessary nor appropriate in 
outpatient and inpatient settings1,3. AMR is a multifactorial issue that must be addressed on 
multiple fronts35. Some suggest a two-pronged approach: developing new antimicrobials to 
fight resistant strains while limiting use of current drugs to reduce rising resistance rates36. 
Our study will focus on the stewardship of current antimicrobials in hospitals. 
Several organizations, including the Centers for Disease Control and Prevention 
(CDC) and the Society for Healthcare Epidemiology of America (SHEA), have led national 
efforts to improve infection control and prescribing practices in healthcare settings37. One 
such approach is antimicrobial stewardship programs (ASP), a set of strategies designed to 
improve the appropriate use of antibiotics through optimal drug selection, dosage, duration 
of treatment, and administration. ASPs seek to provide effective treatment to patients while 
minimizing unintended consequences of antibiotic use37. 
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In 2014, the CDC started recommending the adoption of ASPs by hospitals, and they 
have published a checklist to assist with implementing the seven core components of 
ASPs38, which the CDC considers a minimum standard in hospitals. Those seven elements 
are related to the hospital’s infrastructure and implementation of activities related to 
antimicrobial stewardship26. Veteran’s Affairs (VA) Medical Centers have required ASPs 
since 2014. Moreover, through CDC’s National Healthcare Safety Network (NHSN), acute 
care hospitals are currently required by the Centers for Medicare and Medicaid Services 
(CMS) to report five types of healthcare-associated infections (HAIs): central line-associated 
bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), select 
surgical site infections (SSI), Clostridioides difficile (C.diff) infections, and methicillin-
resistant Staphylococcus aureus (MRSA) infections39.  
Other initiatives also include the US Government’s AMR Challenge, which started at 
the end of 201840, and the Antibiotic Use and Resistance module within NHSN reporting 
system41. The latter is currently optional, but some states have moved towards mandating its 
use42. Additionally, the CDC has recently increased funding for public health departments to 
work on and implement stewardship activities at the state and local levels43. 
While MRSA results from the development of resistant strains, C. diff is not 
technically a resistant bacteria; instead, C. diff is a bacteria with innate resistance to many 
antibiotics. It causes diarrheal disease after exposure to antibiotics which deplete the native 
microbiome and allow for its overpopulation. For that reason, C. diff infection is considered 
an antibiotic adverse event and indicator of antimicrobial use, which is also why it is used as 
an outcome in several studies addressing antimicrobial stewardship44,45 and prescribing 
practices46,47. ASPs are universally recognized as essential tools in healthcare system 
infection control efforts4; In hospitals, ASPs are associated with shorter hospitalizations and 
decreased antimicrobial consumption5.  
At the state level, California has pioneered efforts to address AMR. In 2008, 
California started requiring hospitals to report rates of HAIs48, and it has been the only state 
to mandate ASP in US hospitals since 201549. In 2014, California’s Senate Bill (SB) 1311, 
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required that, by July 1 2015, all California acute care hospitals: (1) adopt and implement an 
ASP in accordance with federal and professional guidelines (e.g., monitoring and evaluation 
of the judicious use of antimicrobials); (2) form a physician-led multidisciplinary antimicrobial 
stewardship committee; (3) appoint to that committee a physician or pharmacist with 
expertise in antimicrobial stewardship through prior training or continued education; and (4) 
report ASP activities to appropriate hospital committees leading quality improvement 
activities25. 
After the passage of the SB 1311, the percentage of hospitals in California which met 
CDC’s 7 core elements for ASPs26 increased from 59.3% in 2014 to 69.2% in 201514 and 
81% in 201627; however the effect of the CA law on AMR-related outcomes is still unknown. 
Although many studies examine ASPs at the hospital level, most analyze its impact on 
prescribing practices and antibiotics use11,12,15–17 rather than directly on AMR rates. One of 
the major reasons for the lack of more assertive investigation is that information on ASPs 
and AMR rates are not generally available in publicly available datasets. 
The present study estimates the impact of passing an ASP mandate in California (SB 
1311) on MRSA and C. diff rates in acute care hospitals. Our hypothesis is that after 2015, 
MRSA and C. diff rates in acute care hospitals dropped significantly in California compared 
to other states. This study provides a novel approach to estimating the effect of such a 
mandate and can assist policymakers and healthcare administrators to make informed 
decisions on the implementation of ASPs. 
Methods 
Data sources 
We merged 2013-2017 hospital-level data from the Centers for Medicare & Medicaid 
Services’ (CMS) HospitalCompare, Provider of Service File and Medicare Cost Reports files. 
HospitalCompare compiles information about quality of care from over 4,000 Medicare-
certified hospitals. Provider of Service Files contain data on hospital characteristics and type 
of services provided, and Medicare Cost Reports include utilization and cost data as well as 
facility characteristics for all Medicare-certified providers. 
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Subjects 
We identified all CMS-certified acute care hospitals in the US for which MRSA/C. 
diff standardized infection ratio (SIR) data were available from 2013 through 2017. We 
excluded VA hospitals (different data collection period), children’s hospitals (different case 
mix/hospital epidemiology), and critical access hospitals. The latter are required to report 
infection data only in some states, and most do not have the minimum number of infections 
required to calculate SIR. 
Measures 
We had two primary outcomes: MRSA SIR and C. diff SIR. The Hospital Compare 
system uses infection data from the CDC’s NHSN, which calculates each hospital’s MRSA 
SIR (ratio of MRSA bacteremia laboratory-identified events to the predicted number of 
MRSA bacteremia events) and C. diff SIR (ratio of C. diff laboratory-identified events to the 
predicted number of C. diff events). 
MRSA predicted events are calculated by the NHSN based on admission prevalence 
rate of MRSA infections, average length of stay, medical school affiliation, type of hospital, 
number of ICU beds, and amount of MRSA infections identified in the emergency 
department and/or observation units. C. diff predicted events are calculated using the type of 
laboratory test used to identify C. diff infection, whether the hospital has emergency 
departments and/or observation units that collect stool specimens for C. diff testing, facility 
bed size, number of ICU beds, medical school affiliation, admission prevalence rate of C. diff 
infections, and type of hospital. The MRSA/C. diff SIR is calculated only for hospitals with at 
least one predicted event39. 
Our main explanatory variables are interactions between a dichotomous indicator of 
whether a hospital is located in California and the years after the mandate. Time-varying 
control variables included in the models were: medical school affiliation, bed count, quality 
accreditation, number of changes in ownership, compliance with CMS requirements, % 
intensive care unit beds, average length of stay, patient safety index, and 30-day 
readmissions rate. Operational definitions for each variable can be found in Table 3.1. 
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Analysis 
We estimated a difference-in-difference (DID) model with hospital fixed effects (FE) 
for each outcome (MRSA SIR and C. diff SIR). We chose hospital FE because it controls for 
both unobserved as well as observed time-invariant hospital-specific characteristics, such as 
location (state, rural vs urban), hospital ownership, teaching status, specialty hospital, 
patient case mix, and structural factors, for example, infection control team, number/distance 
of sinks around hospital rooms, ability to track lab results electronically, safe surgery check 
lists, etc. Those characteristics are likely related to both our key variable of interest (being in 
California) and our outcomes (MRSA/C. diff SIR) and could confound the relationship 
estimated. Since several of these variables are not observed and mostly time-invariant, 
Hospital FE was chosen over other estimation methods. 
We confirmed our model specification by using Hausman tests between a FE vs 
ordinary least squares model, and a FE vs random effects model. In both cases, coefficients 
in the FE model were significantly different from the other estimation methods, therefore, we 
selected the FE estimation to obtain consistent parameter estimates. 
For the DID approach to provide unbiased estimates, two assumptions should hold. 
First, California is the only state being impacted by the policy change and there is no other 
shock happening at the same time; this assumption is reasonable as California was the only 
state to pass such legislation in the study period (2013-2017)49. Second, California and the 
other states should have parallel trends for MRSA and C. diff SIR in the pre-treatment 
period. This assumption was tested by the inclusion of an interaction between each year and 
our key explanatory variable. Robust standard errors were used to address 
heteroscedasticity among hospitals with varying sizes. 
For sensitivity analyses, we estimated the models again including healthcare-
associated infection (HAI) variables as controls since HAIs may be confounders in the 
estimated relationship. We also estimated the models again excluding states with <30% and 
<40% hospital adoption of the CDC’s 7 core components for ASP from the control group. 
Since California had an initial high compliance with the 7 core elements, hospitals in states 
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with higher compliance could be a better counterfactual for hospitals California in this 
analysis. 
Results 
We included data for 2,016 and 3,163 acute care hospitals in the US in the MRSA 
and C. diff models respectively, which corresponds to 51.9% and 81.5% of the total acute 
care hospitals in the country. For MRSA, the SIR peaked in 2015 and then started 
decreasing in CA hospitals; other states had a less steep upward trend for MRSA in 2015 
(Figure 3.1). For C. diff, trends were very similar between CA and other states before the 
mandate with a steeper decrease in CA after the mandate (Figure 3.2). 
Table 3.1 provides descriptive statistics for California hospitals versus hospitals in 
other states before the mandate. In 2013, the average SIR in CA hospitals was 0.79 for 
MRSA (versus 0.94 in other states) and 1.01 for C. diff (versus 0.77 in other states). In terms 
of hospital characteristics, CA hospitals were larger, had a higher percentage of ICU beds 
and quality accredited hospitals, and a lower percentage of hospitals that were teaching, 
rural, had changed ownership, and were compliant with CMS requirements, compared to 
other states (Table 3.1). The sample size in both Tables 3.1 and 3.2 is larger for the C. diff 
model because there were more hospitals for which C. diff SIR was available, since that is a 
more common infection. 
Table 3.2 provides adjusted estimates from the fixed effects regressions. Compared 
to hospitals in other states, CA hospitals had increases (p<0.05) of 23%, 30%, and 20% in 
their MRSA SIR in 2015, 2016 and 2017, respectively, although there was a downward trend 
after 2016 relative to other states. CA hospitals were associated with a 20% (p<0.001) 
decrease in their C. diff SIR only in 2017 (Table 3.2). Time trends were significant in 2015 
and 2017 in the MRSA model and in 2015 and 2016 in the C. diff model. Quality 
accreditation was associated with an increased MRSA SIR. 
In sensitivity analyses, results were robust to the inclusion of other healthcare-
associated infection variables and the exclusion of states with <30% and <40% hospital 
adoption of the CDC’s 7 core components for ASP. 
 23 
Discussion 
We analyzed whether California’s SB 1311 supporting ASPs reduced MRSA and C. 
diff infections in acute care hospitals. Our results show that the CA mandate had significant 
associations with MRSA/C. diff SIRs; surprisingly, that association was in the opposite 
direction for MRSA. 
C. diff SIR decreased after the mandate 
Our findings support our hypothesis that the mandate in California would be 
associated with a reduction in the SIR for C. diff. The mandate introduced in SB 1311 was 
associated with a significant decrease in C. diff SIR in 2017, but a sharper downward trend 
can be observed in 2015 compared to other states (Figure 3.2). Other studies have also 
shown a decrease in C. diff rates after restricting antimicrobial use50,51. One study showed a 
19% decrease in C. diff SIR after implementing antibiotic preauthorization combined with 
clinician education52. Another one detected a decrease as large as 66% in incidence of C. 
diff infections (incidence rate ratio = 0.34) after implementing revised antibiotic guidelines50. 
Moreover, it is estimated that hospital antibiotic prescribing could be improved in 37% 
of the cases, and a 30% reduction in broad-spectrum antibiotic use could result in a 26% 
decrease in C. diff infections53. In the outpatient setting a 10% reduction in antibiotic 
prescribing was associated with a 17% decrease in C. diff rates47. 
In a systematic literature review, ASP interventions in several different countries were 
associated with a decrease in C. diff incidence in 62.5% of the studies analyzed - especially 
in those implementing antimicrobial use restrictions, despite heterogeneity of interventions 
and ways in which outcomes were reported44. These findings are consistent with the fact that 
antibiotic use is the main driver for C. diff; therefore, C. diff rates should respond quicker to 
changes in ASPs compared to MRSA54. 
MRSA SIR increased after the mandate 
One plausible explanation for the increase in the MRSA SIR in CA is that hospitals 
may have introduced processes and structures to proactively identify AMR cases (including 
MRSA), which peaked in 2015, and then started decreasing (Figure 3.1). Notably, California 
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had a lower MRSA SIR before the enactment of SB 1311, which may also contribute to our 
findings. 
One possible reason for the increased MRSA is because the timeframe of this study 
coincided with the recent increased attention to the opioid epidemic, which has led to an 
increased incidence of MRSA bacteremia55,56. Furthermore, the impact of ASPs is likely 
stronger for gram-negative microorganisms since most of the restricted antibiotics are 
primarily for gram-negative bacteria, which is not the case of MRSA. 
Another explanation is that resistant strains will likely not immediately respond to 
improved stewardship efforts, in part, because MRSA control is also dependent on improving 
infection prevention (i.e., increased hand hygiene, improved environmental disinfection, and 
reducing risk of CLABSI) and MRSA is very prevalent in the community (not only in 
healthcare settings). A 3-year ASP intervention, for example, has also been associated with 
increased MRSA incidence, although results should be interpreted with caution because of 
the small sample and single/international hospital setting57. However, a study that analyzed 
data from 6 post-intervention years found a large significant reduction in MRSA incidence in 
the last two years of the study58. 
MRSA and C. diff SIR increased in 2015 
One explanation for the 2015 increase in both MRSA and C. diff SIR in CA and other 
states was the new baseline and improved method NHSN used to calculate predicted events 
starting in 2015. In prior years the baseline years used to calculate predicted infections were 
2010-2011. According to the CDC, with the new baseline, MRSA/C. diff SIRs should shift 
closer to 1 nationwide59, probably because of the models’ improvement in predicting number 
of infections in each hospital. Since the re-baseline was implemented for all hospitals and, 
therefore, states nationwide and we also included time fixed effects in our analysis, this 
change should not be biasing our estimates and our results should still reflect the isolated 
effect of the mandate in CA. 
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Other ASP initiatives 
California has been the only state to pass a mandate with specific ASP requirements 
as of 201749; however, several factors may have increased ASP in hospitals in other states. 
One factor includes a voluntary adoption of hospital ASPs nationwide after the CDC 
launched the 7 core components for ASP6,45 and the Joint Commission announced their new 
antimicrobial stewardship requirements that went into effect in 201760. Both programs affect 
all CMS-certified hospitals nationwide, so our estimates should still be unbiased. 
Regional and local initiatives may also increase ASPs. For example, Missouri Senate 
Bill 579, passed in 2016, requires strict reporting of HAIs and implementation of ASPs 
statewide by the end of 2017, although it does not provide specific ASP standards to be 
implemented61. Moreover, the largest healthcare system in Utah has been actively promoting 
ASP implementation in small community hospitals in the past few years62. Despite those 
scattered initiatives, we can still observe a significant impact of the CA mandate in acute 
care hospitals. 
Limitations 
We identified several limitations of our study. First, we could only assess 2 years of 
post-intervention data; to the extent that MRSA and C. diff rates would continue to fall, we 
would underestimate the impact of the legislation. Second, although CA hospitals’ adoption 
of the CDC 7 core components for ASP increased from 58% in 2014 to 81% in 201627, we 
are not able to estimate the differential impact of specific antimicrobial policies or ASP 
components, only the overall impact of the mandate. Since ASP adoption did not reach 
100% by 2017, that overall impact may have been attenuated by the few hospitals that did 
not adopt the minimum standard ASP proposed in the mandate. We are also not able to 
directly assess antimicrobial use as a mediating factor between ASP and AMR. 
Third, since fixed effect models prioritize addressing bias over precision, we may 
have failed to detect smaller, statistically significant differences. There are also limitations for 
the external generalizability of the results, which can only be extrapolated for adult acute 
care hospitals not part of the VA system that have reported at least one MRSA/C. diff case 
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to the NHSN. Results may differ for other microorganisms; we restricted our study to MRSA 
and C. diff because data are publicly available through Hospital Compare. Finally, even 
though our data support the parallel trends assumption, we only have two years of pre-
treatment data and are not able to verify time trends before that period. 
Conclusion & Policy Implications 
The CA mandate was associated with a decrease in C. diff rates in 2017. A sharper 
decrease in C. diff after 2015 is consistent with the fact that C. diff rates are driven largely by 
use of antibiotics. Contrary to our hypothesis, the CA ASP mandate was not associated with 
an immediate decrease in MRSA SIR. In response to the CA mandate, hospitals may have 
proactively identified AMR cases, which peaked in 2015, and then started decreasing as an 
expected lagged response to the mandate. 
The effect of the mandate may have been diluted by the Joint Commission’s 2016 
nationwide ASP requirements, but we were still able to identify a significant impact in both 
outcome measures. More data on post-intervention years are needed to assess the long-
term impact of the mandate. 
This study has several policy implications. It is the first to shed light on a major and 
persistent healthcare problem by measuring the impact of a statewide ASP mandate. By 
doing so, it provides evidence on the effectiveness of antimicrobial stewardship at the 
hospital level for decision-makers at various levels of the healthcare system. 
Evidence generated in this study can be used by healthcare administrators to 
understand the impact of antibiotic prescribing practices on patient and financial outcomes in 
their institution, to spur action towards adopting or improving their ASP according to federal 
guidelines, and to bring awareness of a possible under-identification of AMR cases. This 
study’s results can also contribute to continued education of healthcare providers, improving 
their awareness of a broader picture of AMR and how compliance with stewardship actions 
can make an impact towards better healthcare. 
Healthcare advocates and policy makers can use evidence from this study to assist 
hospitals to improve identification and reporting of AMR cases, as well as implement ASPs 
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at the regional/state level. Payers can use these results to create incentive mechanisms for 
the effective adoption of ASPs in terms of antibiotic use, timely identification of AMR cases, 
and decreasing rates of resistance. Since most states in the US do not have ASP legislation 
in place, this study can also serve as evidence for implementing regulation that requires a 
minimum standard ASP in acute care hospitals. Future research should evaluate the effect 
of other ASP mandates as additional states pass this type of regulation. 
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Figures & Tables 
Figure 3.1 SIRa for MRSAb in California versus other states, 2013-2017 
 
a Standardized infection ratio 






Figure 3.2 SIRa for C. diffb in California versus other states, 2013-2017 
 
a Standardized infection ratio 






Table 3.1 Descriptive statistics for MRSAa and C. diffb model by California versus other 
states in 2013 
 
MRSA Model C. diff Model 
Variable Other States 
(1,652) 
CA (215) p-value Other States 
(2,754) 
CA (281) p-value 
MRSA SIRc 0.935 0.789 0.012    
C. diff SIR    0.765 1.012 0.000 
Public 13.1% 16.7% 0.146 16.7% 17.8% 0.630 
Private For 
Profit 
17.7% 20.5% 0.328 20.7% 23.5% 0.280 
Private Not For 
Profit 
69.1% 62.8% 0.060 62.6% 58.7% 0.201 
Teaching 47.2% 35.3% 0.001 33.9% 28.5% 0.067 
Rural 11.7% 0.9% 0.000 29.5% 2.8% 0.000 
Bed Count 358.4 312.6 0.009 251.2 265.2 0.335 
Quality 
Accredited 
97.2% 98.1% 0.430 90.8% 97.9% 0.000 
Changes in 






ownership = 1 
32.6% 31.2% 31.1% 29.9% 
Changes in 
ownership >1 




76.3% 65.6% 0.001 77.7% 66.9% 0.000 
Emergency 
Services 
98.7% 97.7% 0.251 96.7% 94.7% 0.084 
% ICUe beds 8.1% 9.6% 0.000 7.7% 9.2% 0.000 
Length of Stay 
(days) 
3.6 3.5 0.038 3.4 3.4 0.462 
ICU Services 94.2% 96.7% 0.123 86.9% 95.4% 0.000 
Patient Safety 
Index 
0.875 0.887 0.475 0.858 0.879 0.096 
% Hospital 
Readmissions 
15.7% 15.6% 0.088 15.6% 15.5% 0.049 
a methicillin-resistant Staphylococcus aureus 
b Clostridioides difficile 
c Standardized infection ratio 
d Centers for Medicare and Medicaid Services 





Table 3.2 Regression-adjusted estimates for the effect of the ASPa mandate in California on 
MRSAb and C. diffc SIRsd, 2013-2017 
 
MRSA MODEL C. DIFF MODEL  
VARIABLE b(SE) b(SE)  












































































N 8,595 14,245 
R2 0.011 0.031 
a Antimicrobial Stewardship Program 
b methicillin-resistant Staphylococcus aureus 
c Clostridioides difficile 
d Standardized infection ratios 
e Centers for Medicare and Medicaid Services 







CHAPTER 4. ASSOCIATION BETWEEN STATEWIDE ADOPTION OF THE CDC’S 7 
CORE ELEMENTS OF ANTIMICROBIAL STEWARDSHIP PROGRAMS AND RATES OF 
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS AND CLOSTRIDIOIDES 
DIFFICILE IN US STATES 
Overview 
Objective: Measure the association between statewide adoption of the Centers for 
Disease Control and Prevention’s (CDC) antimicrobial stewardship program (ASP) 7 core 
components and hospital methicillin-resistant Staphylococcus aureus (MRSA) and 
Clostridioides difficile (C. diff) rates in US states. Hypothesis: States with a higher 
percentage of compliance to CDC’s 7 core components for ASPs will have significantly lower 
MRSA and C. diff rates. Participants: all US states. Design: Observational longitudinal 
study. Methods: Data: We used 2014-2016 data from HospitalCompare, Provider of Service 
File, Medicare Cost Reports, and the Patient Safety Atlas website. Outcomes: Methicillin-
resistant staphylococcus aureus (MRSA) standardized infection ratio (SIR) and 
Clostridioides difficile SIR. Key explanatory variable: percentage of hospitals that meet the 
CDC’s 7 core components for ASP in each state. Analysis: We estimated state and time 
fixed effects models with time-variant controls and weighted our analyses by number of 
hospitals in the state. Results: The percentage of hospitals meeting the CDC’s 7 core 
components for ASP between 2014 and 2016 increased in all states. A one percentage point 
increase in %ASP compliance was associated with a 0.3% decrease (p<0.01) in C. diff 
infections in 2016 relative to 2014. We did not find an effect on MRSA infections. 
Conclusions: Comprehensive ASPs can positively impact C. diff SIR in acute care 
hospitals. We did not find evidence of an impact on MRSA SIR, probably due to the short 




Antimicrobial resistance (AMR) is a major public health threat lying at the intersection 
of healthcare quality and global health security1,21. In the US in 2013, AMR resulted in 
23,000 deaths, $20 billion in direct healthcare costs and $35 billion in overall societal costs1. 
Resistance to the first antimicrobial, penicillin, was reported in 1942, soon after its 
discovery63. AMR is not a novel problem, but it has recently gained great attention because 
of a rapid increase in resistance rates and the small number of new antimicrobial agents22. It 
takes several years for a new antibiotic to be developed and much shorter time for bacteria 
to become resistant to it. 
Misuse and overuse of antimicrobials are major causes of AMR, such as methicillin-
resistant Staphylococcus aureus (MRSA) infections. There is an important opportunity for 
reducing the incidence and impact of AMR because up to 50% of all antimicrobials 
prescribed in US acute care hospitals are unnecessary or inappropriate64–67. Beyond 
resistance, incorrect antibiotic prescribing can also lead to adverse events (sometimes 
severe) and ~250,000 Clostridioides difficile (C. diff) infections in hospitalized patients every 
year1, with no therapeutic benefit53,68,69. C. diff is not technically a resistant bacteria but it has 
an innate resistance to many antibiotics and is vastly used as a marker for antimicrobial use 
because it thrives when the normal human microbiome is killed by the use of antimicrobials. 
As a management tool for hospitals, antimicrobial stewardship programs (ASPs) can 
help ensure that antimicrobials are only prescribed when needed and that the right 
antimicrobial, dose and duration of treatment are being prescribed26. Although ASPs can 
take different approaches (e.g., antibiotic time outs, prior authorization, prospective audit and 
feedback), all involve stricter assessment and monitoring of antimicrobial use and 
sometimes restricting the use of broad spectrum agents5,26. 
A growing body of evidence has shown that ASPs can optimize antimicrobial 
use18,70,71, reduce adverse events18 and resistance rates72, improving quality of care and 
patient safety. Reduced antimicrobial use has not been shown to negatively affect, and may 
improve, patient outcomes73. As noted, most ASP literature focuses on prescribing practices 
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or antimicrobial use5,71,74 rather than resistance rates. Moreover, most studies that assessed 
the impact of ASP on infection rates were done in a single and/or international setting, so 
external generalizability is compromised44. 
Controlling the emergence and spread of resistant microorganisms is a national 
priority. The Centers for Disease Control and Prevention (CDC) has launched a series of 
initiatives and guidelines to address the problem. In 2006, the CDC published guidelines on 
managing multi-drug resistant organisms in healthcare settings75; in 2009, it launched the 
“Get Smart for Healthcare Campaign”, to promote improved antibiotic use; and in 2013, it 
published a thorough report on the epidemiology and morbidity of resistant bacteria and C. 
diff 1, and listed the “loss of antibiotic protection” as one of the top public health concerns in 
the country76.  
Finally, in 2014, the CDC launched specific guidelines for ASPs in acute care 
hospitals as well as other healthcare settings26. Those guidelines add to the previous work of 
the Society for Healthcare Epidemiology of America, Infectious Disease Society of America, 
and The Joint Commission26,77. It sets a minimum standard, with 7 core elements for 
hospitals’ ASPs: leadership commitment, accountability, drug expertise, action, tracking, 
reporting and education26. 
Despite these efforts, a national survey found that only 64% of hospitals in the 
country had some type of ASP policy in place in 2011. Larger, urban and teaching hospitals 
were more likely to have such policies; antibiograms and antimicrobial restriction policies 
were the most common78. Another nationwide survey conducted in 2014 found that 39% of 
acute care hospitals had implemented CDC’s 7 core elements for ASPs. At the state level, 
uptake ranged from 7-58%6. In 2015, that increased to 48.1%, with the highest increase in 
the leadership commitment component79. Larger hospitals and leadership support were 
associated with a comprehensive ASP in 2014 and 201579,80, teaching status was also 
significantly associated with the presence of ASP in 201579. 
Despite CDC’s recent release of guidelines for a minimum standard ASP and its 
assessment in hospitals, the effect of implementing the 7 core elements on resistance rates 
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and C. diff infections is still unclear. Furthermore, the impact of ASPs on actual AMR rates in 
hospitals is uncertain or not explored. 
The objective of this study was to examine compliance with CDC’s ASP 7 core 
components between 2014 and 2016, as well as the association between statewide adoption 
of the CDC’s ASP 7 core components and hospital MRSA and C. diff rates in all US states. 
We hypothesized that: (1) compliance with the CDC’s ASP 7 core components would 
increase between 2014 and 2016; and (2) states with a higher percentage of compliance to 
CDC’s 7 core components for ASPs will have significantly lower MRSA and C. diff rates. 
Methods 
Data sources 
We merged 2014-2017 hospital-level data from the Centers for Medicare & Medicaid 
Services’ (CMS) HospitalCompare, Provider of Service File, Medicare Cost Reports, and 
2014-2016 state-level data from CDC’s Patient Safety Atlas website. HospitalCompare 
compiles quality of care information from over 4,000 Medicare-certified hospitals, Provider of 
Service Files contain data on hospital characteristics and type of services provided, and 
Medicare Cost Reports includes utilization and cost data besides facility characteristics 
regarding all Medicare-certified providers. The CDC’s Patient Safety Atlas website has state-
level data on hospital-acquired infections, antimicrobial resistance and ASPs from acute care 
hospitals nationwide, collected through the CDC National Healthcare Safety Network’s 
(NHSN) Patient Safety Component Annual Hospital Survey, which assesses compliance 
with the 7 core components of ASP. 
Subjects 
The study population includes all 50 US states plus DC from 2014-2016. The data 
that were originally at the hospital-level were collapsed at the state-level using hospital size 
weights. Hospital-level data included all Medicare-certified acute care hospitals in the US for 
which MRSA/C. diff standardized infection ratio (SIR) data were available from 2014-2016. 
Veteran Affairs (VA), children’s and critical access hospitals were excluded because of 
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different data collection period, different case mix/hospital epidemiology and lack of reporting 
requirements for infection data, respectively. 
Measures 
Table 4.1 contains operational definitions for each variable. Our two outcomes are 
defined as follows: MRSA SIR is the ratio of MRSA bacteremia laboratory-identified events 
to the predicted number of MRSA bacteremia events; C. diff SIR is the ratio of C. diff 
laboratory-identified events to the predicted number of C. diff events. SIRs are calculated for 
each hospital by the CDC’s NHSN and made available through HospitalCompare’s data 
system. 
MRSA and C. diff predicted events are calculated by the NHSN based on several 
predictors. For MRSA, they take into account admission prevalence rate of MRSA infections, 
average length of stay, medical school affiliation, type of hospital, number of ICU beds, and 
amount of MRSA infections identified in the emergency department and/or observation units.  
C. diff predicted events are calculated using type of laboratory test used to identify infection, 
whether the hospital has emergency departments and/or observation units that collect stool 
specimens for testing, facility bed size, number of ICU beds, medical school affiliation, 
admission prevalence rate of C. diff infections, and type of hospital. The MRSA and C. diff 
SIRs are calculated only for hospitals with at least one predicted event39. 
Our main regressor is the percentage of hospitals that meet the CDC’s 7 core 
components for ASP in a given state over time (2014-2016). The CDC’s Patient Safety Atlas 
website shows a substantial increase in the percentage of compliance in every state 
nationwide from 2014-201627. Time-variant independent variables included in the models 
were: type of ownership, emergency services, intensive care unit (ICU) services, medical 
school affiliation, bed count, quality accreditation, number of changes in ownership, 
compliance with CMS requirements, %ICU beds, average length of stay, patient safety 
index, and 30-day readmissions rate.  
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Analysis 
First, we used descriptive statistics to measure state-level variation in the percentage 
of hospitals meeting the CDC’s 7 core components for ASP between 2014-2016. Then, for 
each outcome, we estimated a set of different models using state fixed effects (FE). 
We chose state FE because there are a number of time-invariant unmeasured 
confounders to the relationship between ASP and resistance/C. diff rates. These include 
location (state, rural vs urban), hospital ownership, teaching status, specialty hospital, 
patient case mix and structural factors. Since some of these variables are unobserved, we 
are not able to verify whether they are truly time-invariant, but we assume they have very 
little variation, if any variation at all. 
As we used state-level analyses due to the availability of ASP data only at the state 
level, hospital data were aggregated at the state level using hospital size weights. The 
analyses were weighted by number of hospitals in each state, and we controlled for the time-
varying characteristics listed in Table 4.1. In terms of model specification, we ran a Hausman 
test to assess whether the FE model was preferred to a random effects model. 
We also tested using a lagged explanatory variable (2014-2016 ASP data and 2015-
2017 outcomes) to address a possible reverse causation, and an interaction between ASP 
and time (years) to test whether there could be differential treatment effects in each specific 
year. Moreover, we re-estimated the models using hospital-level data, even though there 
was ASP variation only at the state level (Appendices A.1-A.3). 
Results 
Increases in the percentage of hospitals meeting the CDC’s 7 core components for 
ASP between 2014 and 2016 ranged from 6-62% points (Figure 4.1). States with a smaller 
absolute increase usually had a higher percentage in 2014. For example, states with ≥50% 
compliance in 2014, such as AZ, CA, ID, MA, ME, NY and UT, had only 6-26% point 
increases in ASP compliance by 2016. Similarly, states with only ≤29% compliance in 2014, 
such as CT, DC, HI, TN and WV, had the highest absolute increases in percentage of 
hospitals meeting the 7 core components (36-62% points). 
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We hypothesized that states with a higher percentage of compliance to CDC’s 7 core 
components for ASPs would have significantly lower MRSA and C. diff rates. Our findings do 
not support our hypothesis for MRSA (Table 4.2). However, there was support for our 
hypothesis in the C. diff model where ASP compliance was interacted with year. A one 
percentage point increase in ASP compliance was associated with a 0.3% decrease 
(p<0.01) in C. diff infections in 2016 relative to 2014 (Table 4.3). This result suggests a 
differential treatment effect of increasing ASP compliance at the state level across years. 
We did not find evidence of a lagged effect of %ASP compliance in any of the 
models. Results in the MRSA and C. diff models were consistent in both state-level and 
hospital-level analyses (Appendices A.1-A.3). 
Discussion 
AMR is a major public health threat resulting in extensive morbidity, mortality, and 
health care costs. ASPs that encourage compliance with 7 core components identified by the 
CDC have the potential to reduce AMR. In our study of all US states, we tested two 
hypotheses: (1) compliance with the CDC’s ASP 7 core components would increase 
between 2014 and 2016 and (2) states with a higher percentage of compliance to CDC’s 7 
core components for ASPs will have significantly lower MRSA and C. diff rates. Our results 
show that there has been an increase in compliance with the CDC’s 7 core components 
nationwide, which was associated with a decrease in C. diff infections. However, we did not 
find an association with MRSA infections. 
Increased compliance with 7 core components 
As hypothesized, compliance with the CDC’s 7 core components for ASP increased 
in every US state from 2014-2016. Nationally, the proportion of hospitals that met the 7 core 
components increased from 39% in 20146 to 48% in 201549 and 64% in 201627. Not 
surprisingly, increases in compliance were greater in states with lower compliance in the 
initial study period. Increases are mostly driven by recent national policies which encourage 
ASP to be implemented in all healthcare facilities, such as the National Action plan for 
combating antibiotic resistance81, the ASP Guidelines by the Society for Healthcare 
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Epidemiology of America (SHEA)82, and The Joint Commission Standards for Antimicrobial 
Stewardship77,83. 
Despite nationwide increases in ASP adoption, compliance varies regionally. States 
with a higher percentage of compliance are closer to the west or east coast as opposed to 
states in the center of the country49. Studies that had access to more granular data were 
able to identify that larger (>200 beds) and teaching hospitals were more likely to have all 7 
core elements implemented49,78,79. The core component “Action” was the most commonly 
implemented, although that could encompass a range of different facility-specific activities. 
“Leadership Commitment”, such as written support from administrators and ASP-related 
compensation, was the strongest predictor for a hospital meeting the 7 core components49,79. 
Implementing the 7 core components has been associated with up to a 10% 
decrease in antimicrobial use in a large healthcare system84, but an ideal level of 
antimicrobial use in hospitals is not known. However, the decrease in antimicrobial use can 
certainly improve antimicrobial-related adverse events. With national support and local 
implementation of stewardship activities, the judicious use of antimicrobials can be achieved, 
and emergence of resistance can be contained. 
ASP associated with decreased C. diff infections 
As hypothesized, ASP compliance with CDC’s Core Elements was associated with a 
significant decrease in C. diff SIR in 2016 relative to 2014. One reason for why we observe 
that effect in the interaction model only in 2016 is because of the recent increase in ASP 
compliance. Since ASP compliance increased in every state since 2014, we were able to 
detect an effect in 2016. 
This result is consistent with previous studies conducted in single hospital 
settings44,50,52. The VA system also reported declining C. diff infection rates after 
implementing national stewardship activities74. A reduction in C. diff infections has been 
associated with decreased antibiotic prescribing in outpatient settings as well47. Restrictive 
and persuasive (e.g., audit and feedback) stewardship strategies were found to be more 
effective in decreasing C. diff rates44,85–88. 
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Moreover, ASPs may sometimes include disease-specific policies, such as 
guidelines for treatment of C. diff infection, which recommend stopping unnecessary 
antimicrobials for any patient with C. diff infection26,89. Better clinical response and reduced 
risk of recurrence follow as a result89,90 and may also explain the association between ASP 
and reduced C. diff rates in this study. In summary, our study results are consistent with 
evidence from single settings and other venues of healthcare. 
No effect on MRSA infections 
Our hypothesis was not supported for MRSA. Our study did not find evidence of an 
effect of ASP on MRSA infections. There are several possible explanations for this 
difference. First, resistant microorganisms such as MRSA take longer to respond to ASP 
changes than C. diff since the latter is more of an adverse event, so the 3-year period in our 
study may not have been sufficient to capture the effect on MRSA. Large, nationwide studies 
that found an effect of ASP on rates of MRSA or other resistant bacteria were 7-16 years 
long and were done outside of the US91–93. 
Second, resistant strains may also require higher levels of ASP compliance or 
specific restriction policies to impact their infection rates in hospitals. A systematic literature 
review found large variance in resistant microbe outcomes when assessing the impact of 
interventions to improve antibiotic prescribing94. Mixed results are likely explained by 
prevalence density of MRSA and intensity of the intervention in different studies92. 
As an example of varying ASP interventions, two international studies combined 
antimicrobial stewardship with hand hygiene interventions and detected a decline in several 
strains of MRSA95,96. Our general measure for ASP does not capture that level of granularity 
in stewardship activities to understand the effective components of those programs. 
Limitations 
There are several limitations in this study. First, we only had 3 years of state-level 
ASP data, which may have decreased our statistical power in the state-level analyses. 
Second, we only had access to percentage of hospitals that met all 7 CDC core elements, 
rather than the distribution of each specific element hospitals adopted and specific 
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stewardship activities at the hospital level. Therefore, we could not assess the impact of 
specific core elements on C. diff and MRSA rates. Moreover, because we lacked data on 
stewardship strategies, we had to use a more general measure for ASP in this study, which 
may not have enough granularity to understand its relationship with resistant infections. 
Third, MRSA is an important and publicly available measure but may not be ideal to 
reflect changes in ASPs in the short term. MRSA is an endemic infection and may take 
several years to respond to improvements in antimicrobial prescribing practices. Finally, we 
are not be able to estimate causal relationships since there may be unmeasured residual 
confounders in the analyses. For example, patient safety programs in hospitals could have 
some overlap with the CDC’s 7 core elements and impact resistant infections and C. diff 
rates as well, although that is somewhat controlled for by using a FE estimation. 
Conclusion & Policy Implications 
Our study found evidence of a positive impact of comprehensive ASPs on C. diff SIR 
in acute care hospitals. Even though compliance with the CDC’s 7 Core Components has 
increased in all states nationwide, we did not find evidence of an impact on MRSA SIR, 
probably due to the short length of the study and variety of stewardship strategies that ASPs 
may implement. 
This study has a number of policy implications. It provides a novel approach to 
estimating the effect of hospital ASP on infection outcomes nationwide and, therefore, 
important evidence to the incipient body of literature in the field. Furthermore, this research 
measures the impact of guideline-compliant ASPs (e.g., meeting CDC’s 7 core components), 
which has not been done before and may provide an incentive for researchers, policy 
makers, payers, hospital administrators and healthcare providers to promote and adopt 
comprehensive ASPs. 
Perhaps most importantly, our findings suggest that a nationwide policy to reduce 
AMR was successful in preventing C. diff. Different strategies or a longer time horizon may 
be required for resistant organisms. Policy makers can use insights from this study to 
advocate for ASP. Payers may also use evidence from this study to link comprehensive ASP 
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implementation to financial incentives or penalties for those hospitals with SIRs above a 
certain threshold. 
At the healthcare setting level, administrators can use our results to leverage 
momentum for the local implementation of all components of hospital ASPs and education of 
healthcare personnel. Providers may use it for continued education and awareness of the 
importance of complying with hospital policies to promote the judicious use of antibiotics and 
control of infection and resistance rates. 
The study of hospital ASPs would greatly benefit from more granular data on the 
components of ASP and type stewardship activities, especially if available at the hospital 
level. Researchers should seek mechanisms to make possible/facilitate obtaining such data 
from governmental health agencies. Since ASP data are available from 2014 on, future 
research will also benefit from longer follow up periods and possibly using other relevant 
microorganisms in addition to the ones used in this study. 
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Figures & Tables 
Figure 4.1 Increase in Antimicrobial Stewardship Programs (ASP) meeting CDC’s 7 core 
components in US hospitals by state, 2014-2016. 
 
Baseline % ASP compliance in 2014: 
States with <20% ASP compliance: DC, IA, ND, VT 
States with 20-29% ASP compliance: AR, CO, CT, HI, KS, LA, MN, MO, MS, NH, OK, SD, TN, VT, WV, WY 
States with 30-39% ASP compliance: AL, DE, IL, IN, KY, MT, NE, NM, OH, OR, RI, TX, WA, WI 
States with 40-49% ASP compliance: AK, FL, GA, MI, NC, NJ, NV, PA, SC, VA 




Table 4.1 Descriptive statistics for MRSAa and C. diffb models, 2014-2016 
Variable US states, 2014-2016 
n=153 
Mean/% (SD) 
MRSA SIRc 0.87 (0.29) 
C. diff SIR 0.91 (0.14) 
% ASP compliance in the state 48.1 (17.5) 
Public 14.0% 
Private for Profit 14.4% 
Private Not for Profit 71.6% 
Teaching 55.5% 
Rural 17.5% 
Bed Count 410 (126) 
Quality Accredited 94.5% 
Changes in ownership = 0 32.0% 
Changes in ownership = 1 28.4% 
Changes in ownership >1 39.6% 
Compliant CMSd requirements 71.9% 
Emergency Services 98.1% 
% ICUe beds 7.6 (1.5) 
Length of Stay (days) 3.6 (0.4) 
ICU Services 92.1% 
Patient Safety Index 0.92 (0.1) 
% Hospital Readmissions 15.3 (0.6) 
a methicillin-resistant Staphylococcus aureus 
b Clostridioides difficile 
c Standardized infection ratio 
d Centers for Medicare and Medicaid Services  






Table 4.2 Regression-adjusted estimates for the association between %ASPsa meeting 
CDC’s 7 core components and MRSAb SIRsc, 2014-2017 
MRSA MODELS State level State level + 
interactions 
State level + 
lagged x 
VARIABLE b(SE) b(SE) b(SE) 




















                   















































































































N 151 151 152 
R2 0.392 0.397 0.484 
a Antimicrobial Stewardship Program 
b methicillin-resistant Staphylococcus aureus 
c Standardized infection ratio 
d Centers for Medicare and Medicaid Services 
e Intensive Care Unit 
* p<0.05  ** p<0.01  *** p<0.001  
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Table 4.3 Regression-adjusted estimates for the association between %ASPsa meeting 
CDC’s 7 core components and C. diffb SIRsc, 2014-2017 
C. DIFF MODELS State level State level + 
interactions 
State level + 
lagged x 
VARIABLE b(SE) b(SE) b(SE) 
















%ASP X 2015  -0.001 
(0.001) 
                
%ASP X 2016  -0.003*** 
(0.001) 
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(0.418) 










































N 151 151 152 
R2 0.667 0.72 0.803 
a Antimicrobial Stewardship Program 
b Clostridioides difficile 
c Standardized infection ratios 
d Centers for Medicare and Medicaid Services 
e Intensive Care Unit 
* p<0.05  ** p<0.01  *** p<0.001
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CHAPTER 5. ARE RATES OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 
AND CLOSTRIDIOIDES DIFFICILE ASSOCIATED WITH QUALITY AND CLINICAL 
OUTCOMES IN US ACUTE CARE HOSPITALS? 
Overview 
Objective: Examine the association between rates of methicillin-resistant 
Staphylococcus aureus (MRSA)/Clostridioides difficile (C. diff) and quality and clinical 
outcomes in US acute care hospitals. Population: All Medicare-certified US acute care 
hospitals with MRSA/C. diff standardized infection ratio (SIR) data available from 2013-2017. 
Data sources: 2013-2017 hospital-level data from the Centers for Medicare & Medicaid 
Services’ HospitalCompare, Provider of Service and Medicare Cost Reports data files. 
Study design: We estimated separate hospital and time fixed effects models for 30-day 
hospital readmissions, length of stay, 30-day mortality and days in the intensive care unit. 
The key explanatory variables were standardized infection ratios for MRSA and C. diff. 
Principal findings: We found no association of MRSA or C. diff rates with any of the four 
outcomes. Conclusions: Our null results add to the mixed evidence in the field. Some 
outcome measures may have not been appropriate because of different collection period 
and limited population represented. Moreover, there are likely residual confounding factors 
for each of the outcomes. Future research should use patient-level data and appropriate 
methods to guide prioritization of efforts to tackle antimicrobial resistance and continued 





The widespread overuse and misuse of antimicrobials cause microorganisms to 
become resistant to treatment63 and make patients susceptible to both resistant infections, 
such as methicillin-resistant Staphylococcus aureus (MRSA), and Clostridioides difficile (C. 
diff) infections. The latter is not technically a resistant bacteria but it thrives when the human 
microbiome is killed by antimicrobials. Antimicrobial resistance (AMR) is a growing problem 
in the US, affecting more than 2 million patients. MRSA invasive infections alone (not 
including wound, skin and soft tissue) impacted 119,000 patients in 2017, resulting in almost 
20,000 deaths in the US97. Additionally, C. diff infections affected 453,000 patients, resulting 
in 29,000 deaths in 201198. AMR and C. diff infections resulted $20 billion in direct 
healthcare costs and $35 billion in overall societal costs in 20131. 
The global scenario is even more disturbing: by 2050, AMR could lead to 10 million 
deaths and cost $100 trillion dollars annually in direct costs and lost global production99. The 
Centers for Disease Control & Prevention (CDC) considers C. diff an “urgent” threat, and 
MRSA may quickly be upgraded from “serious” to “urgent” without ongoing monitoring and 
prevention strategies1. 
Hospitals are reservoirs for AMR because they combine patients who are either 
susceptible to, or already have, resistant pathogens, intensive/prolonged use of 
antimicrobials, and a risk of cross-infections30. Resistant microorganisms can impact clinical 
and quality outcomes in several ways. Patients infected with resistant pathogens are more 
likely to experience delays in the initiation of effective therapy100, longer 
hospitalizations101,102, surgery or other procedures, adverse outcomes (since their treatment 
often requires more toxic therapy)103, clinical failure and recurrent infections104. Furthermore, 
infections that are resistant to all current available treatments have substantial mortality 
rates103.   
The incidence of bacterial infection during inpatient stays in the US is 20.1%. Of 
those infections, 10.8-16.9% are due to multidrug-resistant organisms (MRSA and C. diff 
included)105. Most AMR-related deaths occur in hospitals1. MRSA, C. diff and other 
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healthcare-associated infections (HAIs) are important measures that may reflect the quality 
of care and impact clinical outcomes in hospital settings106,107. In studies using patient-level 
data, compared to infections that are more susceptible to antibiotics, MRSA and C. diff 
infections require prolonged treatment, longer hospital stays, may result in more disability 
and deaths1,108,109, higher healthcare in-hospital and outpatient costs1,105,109,110, and high 
economic burden in terms of productivity losses due to absence from work or death109. 
A comprehensive picture of the prevalence, incidence, mortality and cost of AMR 
remains elusive1,103,111. Studies on the burden and consequences of AMR suffer from 
heterogeneity in setting, sample size, type of pathogen/resistance, outcome measures and 
methods73,104,111,112. Although studies show a greater risk of death for patients with antibiotic-
resistant infections compared to susceptible infections, better estimates of that differential 
risk are needed1,112,113. Therefore, our objective was to examine the association between 
rates of MRSA/C. diff and quality and clinical outcomes in acute care hospitals in the US. We 
hypothesized that higher rates of MRSA and C. diff in acute care hospitals are related to 
higher rates of 30-day hospital readmissions, 30-day mortality, longer length of hospital stay 
and more intensive care unit (ICU) days in US hospitals. 
Methods 
Data Sources 
We merged 2013-2017 hospital-level data from the Centers for Medicare & Medicaid 
Services’ (CMS) HospitalCompare, Provider of Service File and Medicare Cost Reports data 
files. HospitalCompare includes quality of care information from over 4,000 Medicare-
certified hospitals; the Provider of Service Files contain hospital characteristics and type of 
services provided; and Medicare Cost Reports include utilization and cost data as well as 
facility characteristics for all Medicare-certified providers. 
Subjects 
The study population included all Medicare-certified US acute care hospitals for 
which MRSA/C. diff standardized infection ratio (SIR) data were available from 2013-2017. 
The National Healthcare Safety Network (NHSN) does not calculate SIR for hospitals with 
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<1 expected infection, therefore, we excluded those hospitals (Appendix B.1). Veteran 
Affairs (VA), children’s and critical access hospitals were excluded because of different data 
collection periods, different case mix/hospital epidemiology and lack of reporting 
requirements for infection data, respectively. 
Measures 
Table 5.1 contains detailed operational definitions for each variable. Our four 
outcomes were: 30-day hospital readmissions, calculated as the percentage of patients re-
admitted to the hospital within 30 days of discharge (Medicare beneficiaries only, adjusted 
for patient characteristics); length of stay (LoS), calculated as the mean length of inpatient 
days; 30-day mortality, calculated as the weighted average of 30-day mortality for chronic 
obstructive pulmonary disease, heart attack, heart failure, pneumonia and stroke based on 
proportion of hospital stays for each diagnosis114 (included Medicare beneficiaries only and 
is adjusted for patient characteristics); and ICU days, measured as the total number of 
inpatient days spent in the ICU. 
Our two main regressors were: MRSA SIR (ratio of MRSA bacteremia laboratory-
identified events to the predicted number of MRSA bacteremia events) and C. diff SIR (ratio 
of C. diff laboratory-identified events to the predicted number of C. diff events). SIRs were 
calculated for each hospital by the CDC’s NHSN and made available through 
HospitalCompare’s data system.  MRSA predicted events were calculated by the 
NHSN based on admission for prevalence rate of MRSA infections, average length of stay, 
medical school affiliation, type of hospital, number of ICU beds, and amount of MRSA 
infections identified in the emergency department and/or observation units. C. diff predicted 
events were calculated using type of laboratory test used to identify infection, whether the 
hospital has emergency departments and/or observation units that collect stool specimens 
for testing, facility bed size, number of ICU beds, medical school affiliation, admission 
prevalence rate of C. diff infections, and type of hospital. The MRSA/C. diff SIR was 
calculated only for hospitals with at least one predicted event39. 
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Analysis 
We estimated linear hospital and time fixed effects (FE) models for each of our four 
outcomes (30-day hospital readmissions, length of stay, 30-day mortality and ICU days). We 
chose FE because it controls for unmeasured and measured time-invariant confounders at 
the hospital level such as location, hospital type, hospital ownership, population served, 
structure for quality improvement and infection control. Although some of these 
characteristics may not be completely time-invariant, we believe they are largely time-
invariant. 
For each outcome we ran two models, one with MRSA SIR as the main regressor 
and one with C. diff SIR as the main regressor. We controlled for the time-variant 
characteristics listed in Table 5.1. Standard errors were clustered at the state level and the 
analyses were weighted by hospital size. We confirmed the FE specification by using a 
Hausman test between FE and random effects estimation for each model. 
As sensitivity analyses, we added two other HAIs in the models that may be related 
to both MRSA/C. diff infections and quality and clinical patient outcomes: central line-
associated blood stream infection (CLABSI) and catheter-associated urinary tract infection 
(CAUTI). 
Results 
In the models where MRSA was the key explanatory variable, the number of 
hospitals with available data from 2013 to 2017 was 2,016 (30-day readmission), 2,023 
(LoS), 1,907 (30-day mortality) and 1,920 (ICU days). When C. diff was the key explanatory 
variable, the number of hospitals with available data was 3,163 hospitals (30-day 
readmission), 3,177 (LoS), 2,427 (30-day mortality) and 2,774 (ICU days). Characteristics of 
hospitals for the MRSA and C. diff models are presented in Table 5.1. 
In the MRSA models, MRSA SIR was not associated with any of the four outcomes: 
30-day hospital readmissions, LoS, 30-day mortality or ICU days (Table 5.2). Similarly, in the 
C. diff models, C. diff SIR was also not significantly associated with any of the outcomes 
(Table 5.3). The year intercepts were mostly negatively associated with 30-day readmissions 
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and positively associated with LoS, 30-day mortality and ICU days in both MRSA and C. diff 
models. A few control variables were significant as well. For example, teaching status was 
positively associated with 30-day readmissions. Patient Safety Indicator (lower scores reflect 
higher quality) was positively associated with 30-day mortality in both models as well (Tables 
5.2 and 5.3). Results were robust to the inclusion of CLABSI and CAUTI control variables 
(Appendices B.1-B.3). 
Discussion 
The increasing prevalence of AMR among hospitalized patients in the US and around 
the world has been associated with worse patient outcomes (including death), higher health 
care utilization, and greater health care costs in patient-level analysis. Using a national 
sample of US acute care hospitals, we tested the hypothesis that higher rates of MRSA and 
C. diff were associated with higher rates of 30-day hospital readmissions, 30-day mortality, 
longer length of hospital stay and more ICU days in US hospitals. Our findings did not 
support any of these hypotheses. Other studies comparing quality and clinical outcomes for 
patients with MRSA, C. diff or other AMR used patient-level data and were highly 
heterogeneous in terms of setting, methods, comparators and outcomes. They have found 
mixed results for the proposed relationships. Single setting studies and specific comparators 
may have contributed with internal consistency in studies where the difference in outcomes 
were significant. 
30-day readmissions 
Persistence of colonization in patients with previous MRSA and other infections is 
common and may last from 5 months to two years after their last discharge115,116. Around 
61.6% of patients with AMR are readmitted to the hospital within one year of discharge117. 
However, previous studies show high heterogeneity and conflicting results on the effect of 
MRSA on readmissions. A nationwide study using the readmissions database found that 
48.5% of patients with Staphylococcus aureus bacteremia had MRSA bacteremia. Overall 
30-day readmission was 22% with no difference for MRSA patients. However, MRSA had 
more readmissions for bacteremia recurrence118. Several other studies showed that MRSA 
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had no statistical significance on readmissions119,120. However, patients isolated because of 
MRSA had 4.4% higher 30-day readmissions compared to other patients121. In international 
settings, the results were also inconsistent. A study in Australia comparing patients with 
MRSA and susceptible S. aureus found no difference in hospital readmissions122. But in 
Spain, 30-day readmission was 2.2 times higher in patients with HAIs caused by resistant 
pathogens123. 
Recurrence rates for healthcare-associated C. diff infection have been found to be as 
large as 50%124,125, which increases the chance of a return to the hospital. In a single-setting 
study, 27% of patients with a C. diff infection had at least one complication and 20% were re-
admitted to the hospital126. In a larger study, C. diff was also associated with high burden on 
hospital readmissions127. However, other studies did not show such a high burden128. 
In a retrospective cohort study, patients carrying MRSA or C. diff after discharge 
were more likely to be readmitted to a hospital or nursing home compared to non-carriers, 
exposing other facilities to the spread of AMR organisms129. A nationwide study in France 
identified history of C. diff infection as an independent predictor of 90-day hospital 
readmissions130. However, in a Medicare sample, the effect of C. diff on readmissions 
depended on treatment prescribed at discharge131, a factor not considered in most of studies 
looking at this relationship. In light of the body of literature, our study results are not 
surprising given the highly mixed results from previous investigations. 
Length of stay 
A similar pattern is observed in studies assessing the impact of MRSA or C. diff on 
length of hospital stay in terms of heterogeneity in settings, methods and outcomes; 
however, the significance of previous studies was mostly consistent across them, despite 
contrasting with our results. One reason for our null results is that we used hospital-level 
analysis as opposed to patient-level analysis, commonly used in previous studies. 
A large study showed that 18% of patients were diagnosed with C. diff infections with 
average LoS of 13.6 days128. Several studies showed that C. diff and MRSA were associated 
with longer hospital stays129,132. A nationwide study using the readmissions database, 
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showed that patients with MRSA had longer hospitalization118. Patients with MRSA surgical 
infections also had greater LoS than patients120,133. However, a single setting study found no 
difference in LoS for patients with resistant infections123. 
The extent to which resistant infections increased LoS also varies across studies. 
Patients with MRSA stayed 30% longer in the hospital and had 43% higher cost of care121. 
Another study found that patients with MRSA had, on average, an 8-day longer hospital 
stay119. Despite consistent results from other studies, an important factor that was not 
addressed in any of them is reverse causation. Patients with longer LoS are exposed to 
resistant pathogens for longer and, therefore, are more likely to acquire MRSA, C. diff or 
other HAIs, which could also explain the significant results in these studies. In contrast, our 
results did not find a significant association likely because we used hospital-level data, as 
opposed to patient-level data. 
30-day mortality 
Contrary to our null results, several previous studies found MRSA and C. diff to be 
significantly associated with 30-day mortality. Studies related to MRSA were less consistent 
than those addressing C. diff, which could again be explained by the settings and methods 
used. 
A single setting study estimated that AMR might cause more than 40% of deaths 
among patients with resistant HAIs and that 30-day mortality was 1.7 times higher in patients 
with resistant pathogens123. For patients with blood stream MRSA infections, 30-day 
mortality was 16%134. In nationally representative studies of US hospitals, mortality rates 
related to MRSA bacteremia were higher than for susceptible S. aureus108,118. However, 
MRSA had no difference in mortality among surgical patients120 or patients isolated because 
of MRSA121. A long-term cohort study in Australia also did not find any difference in mortality 
among patients with MRSA122. 
Fewer studies on the impact of C. diff were available. An important gap in the 
literature given that 9.3% of patients die within 30 days of C. diff diagnosis98. A large study 
found that around 13% of hospital patients had nosocomial C. diff infections, 15.2% of those 
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died and 1.5% died directly or indirectly of C. diff128. A meta-analysis found C. diff to be 
associated with higher mortality rates compared to patients without C.diff132. C. diff was also 
associated with higher mortality in patients with hospital-acquired pneumonia135. 
Mortality due to AMR is hard to attribute1,135. Currently, there are not specific criteria 
or algorithms to link deaths directly to AMR, ruling out a co-existing illness/condition. Studies 
trying to measure attributable mortality rely on a subjective judgment to distinguish when 
AMR is directly the cause of death, or is contributing or merely related to the death, 
especially in hospital settings where patients tend to accumulate other complications1. As an 
example, a meta-analysis showed that 23% of the included studies found significantly higher 
mortality associated with MRSA bacteremia, while 77% did not find significant results. There 
was significant heterogeneity across the studies due to different estimation methods, 
adjustment for confounders and severity of illness, higher proportion of nosocomial infections 
versus community-acquired infections, source of infections and mortality outcomes113. 
ICU days 
Our results are not surprising compared to the current literature. Studies on the 
impact of MRSA and C. diff on ICU days had mixed results and were also very different in 
terms of methods, setting and patient population. In a long study with pediatric patients, 
MRSA bacteremia resulted in more ICU admissions136. But in a single setting study, resistant 
HAI infections were not associated with more ICU admissions123. In international settings, 
MRSA patients required more ICU care, however, the ICU stay was not longer for MRSA 
patients137. On the other hand, another study showed that MRSA patients had significantly 
longer ICU stay compared to other patients138. However, these results may not be reliable 
because important confounders were not addressed. 
C. diff had higher incidence in ICUs139,140 and a meta-analysis found it to be 
associated with longer ICU stays compared to patients without C.diff132. However, similar to 
the LoS outcome, results are not reliable without properly addressing reverse causation, 
since longer exposure to intensive care may greatly increase the chances of developing C. 
diff and AMR.  
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Most of the cited studies analyze the impact of AMR/C. diff on in-hospital outcomes 
but the hospital perspective is far from a complete picture of the real impact of AMR on 
healthcare and patient outcomes since an important proportion of the care is delivered in 
rehabilitation facilities, nursing homes or even at home. However, access to data from those 
sites is limited103. 
Limitations 
This study has several limitations. First, we used hospital and time FE to control for 
important confounders but in light of the null results, we may have not had enough within 
hospital variation left to detect differences in our outcomes since this is a consistent but 
inefficient method. Moreover, we are only able to estimate associations and not causal 
relationships, especially in the LoS and ICU days models, where reverse causation is likely. 
Our data did not allow for the use of appropriate instrumental or lagged variables because 
the latter would require a shorter time period variable. 
A second limitation may have been the definition of some of our outcomes. Most 
variables in this study were collected from January through December, but 30-day 
readmissions and 30-day mortality were collected from July through June of each year. The 
30-day mortality variable also includes only patients who had one of 5 relevant diagnoses 
and is a 3-year moving average from July to June. These measures may not have been 
good enough to capture the outcome that we intended to analyze because of the different 
timeframe and limited representation of patients. Third, there may be tautological correlation 
between MRSA/C. diff SIR and LoS since LoS is included in the SIRs calculation, although 
older data was used. 
Conclusions & Policy Implications 
This study did not find associations between MRSA and C. diff and our four outcome 
measures: 30-day readmissions, 30-day mortality, length of stay and ICU days. Given the 
mixed results in the current literature, our findings likely reflect the complexity of the task of 
assessing quality and clinical outcomes in the hospital context. Our study highlights the need 
for more publicly available infection data from hospitals. We recognize that patient-level 
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infection data are sensitive since it reflects hospital performance, but such data are needed 
to understand the relationship between AMR and outcomes that are important to patients, 
providers, and health care systems. 
Although we did not find statistically significant associations, comprehending the 
impact of resistant infections on quality and clinical outcomes remains very relevant for 
payers and policymakers as they make funding decisions regarding programs to control and 
prevent the emergence of AMR. Results from this study may help develop the foundation for 
future studies. Future research should use larger samples of patient-level data and test the 
effect of different resistant microorganisms in relevant patient groups or healthcare settings. 
It is also paramount that future research use appropriate methods to control for confounders 
at the patient, hospital and regional level, as well as for reverse causation. As a result, 
reliable evidence will guide future prioritization of efforts to tackle AMR and continued 




Table 5.1 Descriptive statistics for models where MRSAa or C. diffb are the explanatory 
variable, 2013-2017 
Variable MRSA Models 
n=8,806 
Mean/% (SD) 
C. diff Models 
n=14,590 
Mean/% (SD) 
MRSA SIRc 0.93 (0.80)  
C. diff SIR  0.84 (0.50) 
% 30-Day Hospital Readmissions 15.5 (1.03) 15.4 (0.96) 
Length of Stay (days) 3.65 (0.71) 3.41 (0.85) 
% 30-Day Mortality 12.4 (1.30) 12.5 (1.28) 
ICUd Days 7209 (6609) 5143 (5980) 
Public 12.8% 14.9% 
Private For Profit 17.5% 20.4% 
Private Not For Profit 69.7% 64.6% 
Teaching 48.2% 35.5% 
Rural 8.5% 24.6% 
Bed Count 368 (250) 263 (236) 
Quality Accredited 97.9% 93.5% 
Changes in ownership = 0 29.8% 32.2% 
Changes in ownership = 1 32.6% 30.9% 
Changes in ownership >1 37.6% 36.9% 
Compliant with CMSe Requirements 73.6% 75.8% 
Emergency Services 98.1% 96.4% 
% ICU beds 8.3 (5.40) 8.1 (5.83) 
ICU Services 93.2% 88.5% 
Patient Safety Index 0.92 (0.22) 0.91 (0.20) 
a Methicillin-resistant Staphylococcus aureus 
b Clostridioides difficile 
c Standardized infection ratio 
d Intensive Care Unit  
e Centers for Medicare and Medicaid Services 
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Table 5.2 Regression-adjusted estimates for the association between MRSAa SIRb and 




Length of Stay 30-Day 
Mortality 
ICUc Days 
 b(SE) b(SE) b(SE) b(SE) 
MRSA SIR 0.010 0.008 0.006 23.169 
 (0.009) (0.006) (0.009) (50.409) 
Teaching 0.131* -0.030 0.060 715.873 
 (0.064) (0.031) (0.053) (517.922) 
Bed Count -0.000 0.001 -0.000 9.463*** 
 (0.000) (0.000) (0.000) (1.534) 
Quality Accredited 0.159 0.063 0.068 302.271 
 (0.086) (0.033) (0.117) (225.535) 
Changes in 





























%ICU Beds 0.004 -0.012** -0.004 526.651*** 
 (0.004) (0.004) (0.004) (90.957) 
Patient Safety 
Indicator 
0.058 -0.036 0.236** -126.074 
 (0.051) (0.026) (0.069) (273.857) 
2014 -0.321*** 0.028** -0.322*** 186.273** 
 (0.041) (0.009) (0.014) (69.267) 
2015 0.005 0.044** 1.149*** 508.058** 
 (0.056) (0.014) (0.027) (147.838) 
2016 -0.297*** 0.040* 0.832*** 686.847*** 
 (0.060) (0.019) (0.036) (137.506) 
2017 -0.299*** 0.014 0.734*** 661.687*** 
 (0.058) (0.024) (0.040) (162.552) 
Constant 15.683*** 3.453*** 11.873*** 159.835 
 (0.215) (0.268) (0.292) (1408.455) 
N 8754 8606 8284 8149 
r2 0.094 0.020 0.630 0.136 
a Methicillin-resistant Staphylococcus aureus 
b Standardized infection ratio 
c Intensive Care Unit  






Table 5.3 Regression-adjusted estimates for the association between C.diffa SIRb and quality 




Length of Stay 30-Day 
Mortality 
ICUc Days 
 b(SE) b(SE) b(SE) b(SE) 
C. diff SIR 0.011 0.011 0.032 -6.235 
 (0.020) (0.009) (0.024) (91.543) 
Teaching 0.114* -0.014 0.048 573.619 
 (0.054) (0.028) (0.045) (443.620) 
Bed Count -0.000 0.001 -0.000 8.759*** 
 (0.000) (0.000) (0.000) (1.526) 
Quality Accredited 0.152* -0.002 0.057 239.238 
 (0.071) (0.051) (0.104) (186.313) 
Changes in 





























%ICU Beds 0.004 -0.012** -0.002 425.281*** 
 (0.003) (0.004) (0.005) (76.091) 
Patient Safety 
Indicator 
0.045 -0.031 0.214*** -140.534 
 (0.048) (0.026) (0.061) (254.130) 
2014 -0.337*** 0.026** -0.332*** 165.174** 
 (0.036) (0.008) (0.013) (59.577) 
2015 -0.006 0.034* 1.143*** 457.263*** 
 (0.051) (0.013) (0.025) (129.835) 
2016 -0.298*** 0.026 0.826*** 604.467*** 
 (0.051) (0.018) (0.034) (120.523) 
2017 -0.298*** 0.002 0.739*** 570.390*** 
 (0.050) (0.020) (0.036) (136.953) 
Constant 15.673*** 3.485*** 11.899*** 639.801 
 (0.170) (0.262) (0.281) (1191.931) 
N 14499 14300 11055 12814 
r2 0.094 0.015 0.624 0.114 
a Clostridioides difficile 
b Standardized infection ratios 
c Intensive Care Unit 






CHAPTER 6. SUMMARY OF FINDINGS AND POLICY IMPLICATIONS 
Each year, two million Americans acquire serious infections caused by bacteria that 
are resistant to antibiotics resulting in significant morbidity, mortality, health care utilization, 
and costs. This study addressed the persistent problem of AMR and other consequences of 
the injudicious use of antimicrobials by analyzing state and national programs designed to 
tackle AMR emergence. We also investigated implications of MRSA and C. diff infections for 
healthcare quality and clinical outcomes. This work is motivated by the unchecked growth of 
resistance in the US and across the world and the local, state and national initiatives to 
contain AMR and, ultimately, improve healthcare quality and patient outcomes. 
This research involved three aims. In aim 1, we hypothesized that after the passage 
of a California mandate in 2015, MRSA and C. diff rates in acute care hospitals decreased 
more in California hospitals compared to other states. In aim 2, we hypothesized that 
compliance with the CDC’s ASP 7 core components would increase between 2014 and 2016 
in the US, and hospitals in states with a higher percentage of compliance to CDC’s 7 core 
components for ASPs would have significantly lower MRSA and C. diff rates. In aim 3, our 
hypothesis was that higher rates of MRSA and C. diff in acute care hospitals would be 
related to higher rates of 30-day hospital readmissions, 30-day mortality, longer length of 
stay and more ICU days in US hospitals. 
Summary of Findings 
In all three aims we chose FE estimation methods based on theory and confirmed 
our choice using specification tests. In all aims our sample included hospitals for which 
MRSA/C. diff SIR were available, which excluded hospitals with expected number of 
infections smaller than one. Even though that causes our sample to decrease, it contributes 
for better internal consistency since the excluded hospitals are vastly different than the ones 
with at least one expected infection. We found significant results on the impact of hospital 
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ASP on MRSA and C. diff rates in aims 1 and 2, but no evidence of an association between 
MRSA/C. diff and quality and clinical outcomes in aim 3. 
In aim 1, compared to hospitals in other states, California hospitals had a lower 
average MRSA SIR (0.79 versus 0.94) and C. diff SIR (1.01 versus 0.77). After the mandate, 
California hospitals had significant (p<0.05) increases of 23%, 30%, and 20% in MRSA 
infections in 2015, 2016 and 2017, respectively. Relative to other states, California hospitals 
also had a 20% (p<0.001) decrease in their C. diff SIR, but only in 2017. Although we were 
unable to control for all time-variant confounders, most confounding factors would bias the 
estimates towards the null (e.g., other ASP initiatives being adopted in the comparison 
group); thus, we may have underestimated the effect. However, despite evidence of a 
parallel trend in both MRSA and C. diff models, this assumption may not hold given the short 
panel data and our inability to verify trends before 2013. 
In aim 2, the percentage of hospitals meeting the CDC’s 7 core components for ASP 
between 2014 and 2016 increased in all states. A one percentage point increase in ASP 
compliance was associated with a 0.3% decrease (p<0.01) in C. diff infections in 2016 
relative to 2014. Despite the numerically small effect only in the C. diff model, extrapolating 
would lead to large increases in ASP compliance observed in the real world. For example, a 
10-percentage point increase in ASP compliance at the state level would be associated with 
a 3% decrease in C. diff infections, which represents a significant change. 
We did not find an effect of ASP on MRSA SIR. One explanation may be that we only 
had 3 years of state-level ASP data, which severely limited our analysis. Moreover, our ASP 
data consisted of whether or not a hospital met the 7 core elements of ASP, so we were 
unable to assess specific elements which could affect infection rates. For example, if the 
“leadership” or “action” element are the ones with higher impact, our analysis may have 
been confounded by hospitals that did meet those elements but were not compliant with all 
the 7 core elements. These limitations may also explain the smaller/null impact relative to 
aim 1. Additionally, in Aim 1, we had more clearly defined requirements for hospitals from 
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California, as well as needing to comply with federal guidelines, which probably resulted in 
less variation across the actions that the hospitals were taking in order to comply. 
In aim 3, we did not find evidence of an association between MRSA/C. diff and 30-
day readmissions, length of stay, 30-day mortality and ICU days. The FE estimation may 
have contributed to a possible lack of variation to estimate the effects, (e.g., variation left 
after accounting for hospital and time FE in the models). Additionally, some outcomes such 
as 30-day readmissions and 30-day mortality may not have been good measures because of 
the different time period and limited diagnoses included in the 30-day mortality variable. We 
were also unable to examine reverse causation in the length of stay and ICU days models. 
Previous literature in the field presented high heterogeneity and mixed results, especially in 
studies examining 30-day readmissions, 30-day mortality and ICU days. 
Implications for Practice and Policy 
Overall, our results contribute to a better understanding of how ASPs can impact 
MRSA and C. diff infections and, in turn, how those infections can impact care in US acute 
hospitals. Our results also provide reliable evidence on the effectiveness of hospital ASPs 
for decision-makers to shape policy at various levels of the healthcare system. 
By analyzing a statewide natural experiment in California, we were able to begin to 
unpack the relationship between a statewide ASP mandate and AMR rates for MRSA and C. 
diff. We were also be able to understand how those rates responded to the passage of the 
bill, e.g., time gap between mandate and actual decrease in infections. This understanding is 
important because it addresses a question for policy-makers who are considering a hospital 
ASP mandate with minimum requirements in their state. 
We also provide a timely and new assessment of the impact of hospital ASPs that 
meet the CDC’s 7 core elements, which may be used to inform future ASPs and strategies 
as we provide estimates of the association between the CDC’s 7 core elements and 
common resistant infections. Therefore, this investigation not only adds to the bulk of 
literature, but also addresses important knowledge gaps. 
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In addition, we provide more detailed evidence on the association between relevant 
infections (MRSA and C. diff) and quality and clinical outcomes. Although our initial intent 
was to be able to discern which pathogen has a greater impact on the selected outcomes, 
the absence of evidence, along with mixed results from previous literature, suggest that 
these relationships are complex and need better data to better understand hospital care in 
the context of resistant infections. Armed with better data and reliable evidence, providers, 
policy-makers and healthcare administrators will be able to prioritize specific microorganisms 
in their ASPs. 
Future Research 
This investigation contributes to our understanding of ASPs; however, more research 
is needed. First, we may need to focus on the effect of specific elements of ASPs rather than 
using general measures as we did in this study, which would yield in cleaner analyses. 
Second, it may be useful to generate estimates of the pathways and mediating factors 
between ASPs, infection rates and patient outcomes. Although a more detailed investigation 
of this relationship would require a richer dataset with more granular ASP information. 
Third, Missouri recently passed an ASP bill that was different from California’s in 
several ways. Researchers should examine the implementation of this mandate to 
understand the impact of a less specific ASP mandate on resistant infections. Moreover, the 
Missouri mandate was passed after the announcement of the Joint Commission (JC) ASP 
requirements in 2016. Therefore, its investigation would add to the body of the literature in 
terms of the marginal benefit to the JC requirements. 
Finally, besides comprehending more granular aspects of ASPs, research is needed 
to understand their specific effect on other relevant resistant bacteria as well. As 
carbapenem-resistant Enterobacteriaceae becomes reportable in more states, it should 
become the target of studies on the effect of ASP. Healthcare providers and administrators 
would also profit from studies on ASP implementation, such as ASP types and 
characteristics that are easier to enforce and identification of provider characteristics that are 
associated with higher compliance with ASP policies. 
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As we move forward in the study of the relationships around AMR, we will likely 
enhance research strategies and analytical methods with the increasing bulk of literature, 
allowing for better evidence and better decision-making in the field. With reliable estimates, 
future studies could use cost-effectiveness models to understand the benefit of implementing 
certain ASP strategies to a wider population. Accessing more granular data, such as the 
CDC’s NHSN Annual Hospital Survey, which contain ASP information at the hospital level, 
would also be a step in that direction since it would allow for the development of a better 
statistical plan than was possible in this research. As we contribute to the knowledge in this 
area, we hope that the competent authorities will facilitate access to the needed data.  
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APPENDIX A: CHAPTER 4 SUPPLEMENTAL TABLES  
Appendix Table A.1 Descriptive statistics for hospital-level MRSAa and C. diffb models, 2014-
2016 
Variable MRSA Model 
n=5,194 
Mean/% (SD) 
C. diff Model 
N=8,611 
Mean/% (SD) 
MRSA SIR 0.95 (0.81)  
C. diff SIR  0.88 (0.50) 
% ASP compliance in the state 53.3 (15.71) 52.1 (15.96) 
Public 12.9% 14.8% 
Private for Profit 17.6% 20.5% 
Private Not for Profit 69.5% 64.7% 
Teaching 48.6% 35.8% 
Rural 8.5% 24.5% 
Bed Count 370 (251) 265 (237) 
Quality Accredited 97.9% 93.6% 
Changes in ownership = 0 29.6% 32.0% 
Changes in ownership = 1 32.7% 31.0% 
Changes in ownership >1 37.7% 37.0% 
Compliant CMSc requirements 73.0% 75.3% 
Emergency Services 98.6% 96.9% 
% ICUd beds 8.5 (5.28) 8.3 (5.76) 
Length of Stay (days) 3.66 (0.73) 3.43 (0.88) 
ICU Services 94.9% 90.4% 
Patient Safety Index 0.91 (0.21) 0.90 (0.19) 
% Hospital Readmissions 15.5 (1.01) 15.4 (0.95) 
a methicillin-resistant Staphylococcus aureus 
b Clostridioides difficile 
c Centers for Medicare and Medicaid Services 
d Intensive Care Unit 




Appendix Table A.2 Hospital-level regression-adjusted estimates for the association 
between %ASPsa meeting CDC’s 7 core components and MRSAb SIRsc, 2014-2017 
MRSA MODELS Hospital level Hospital level + 
interactions 
Hospital level + 
lagged x 
VARIABLE b(SE) b(SE) b(SE) 












































































































N 5194 5194 4861 
R2 0.016 0.017 0.016 
a Antimicrobial Stewardship Program 
b methicillin-resistant Staphylococcus aureus 
c Standardized infection ratio 
d Centers for Medicare and Medicaid Services 
e Intensive Care Unit 
* p<0.05 
** p<0.01 
*** p<0.001  
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Appendix Table A.3 Hospital-level regression-adjusted estimates for the association 
between %ASPsa meeting CDC’s 7 core components and C. diffb SIRsc, 2014-2017 
C. DIFF MODELS Hospital level Hospital level + 
interactions 
Hospital level + 
lagged x 
VARIABLE b(SE) b(SE) b(SE) 
















%ASP X 2015  0 
(0.001) 
 





















































































N 8611 8611 8225 
R2 0.031 0.034 0.099 
a Antimicrobial Stewardship Program 
b Clostridioides difficile 
c Standardized infection ratios 
d Centers for Medicare and Medicaid Services 






APPENDIX B: CHAPTER 5 SUPPLEMENTAL TABLES  
Appendix Table B.1 Descriptive statistics for hospitals not included in the models where 
MRSAa or C. diffb were the explanatory variable, 2013-2017. 
Variable Hospitals with MRSA 
SIR missing (2013-17) 
n=7,716 
Mean/% (SD) 
Hospitals with C. diff 
SIR missing (2013-17) 
n=1,858 
Mean/% (SD) 
% 30-Day Hospital Readmissions 15.28 (0.80) 15.23 (0.68) 
Length of Stay (days) 3.11 (1.50) 3.25 (2.55) 
% 30-Day Mortality 12.86 (1.16) 12.85 (1.13) 
ICUd Days 1505 (1346) 845 (2567) 
Public 20.8% 29.7% 
Private For Profit 29.3% 42.5% 
Private Not For Profit 49.9% 27.8% 
Teaching 15.2% 11.8% 
Rural 46.7% 40.5% 
Bed Count 92 (78) 54 (110) 
Quality Accredited 80.4% 60.4% 
Changes in ownership = 0 38.7% 47.1% 
Changes in ownership = 1 28.1% 27.3% 
Changes in ownership >1 33.2% 25.6% 
Compliant with CMSe Requirements 78.3% 75.3% 
Emergency Services 87.1% 67.8% 
% ICU beds 6.17 (6.55) 1.43 (4.02) 
ICU Services 64.9% 15.1% 
Patient Safety Index 0.89 (0.14) 0.90 (0.10) 
a Methicillin-resistant Staphylococcus aureus 
b Clostridioides difficile 
c Standardized infection ratio 
d Intensive Care Unit  
e Centers for Medicare and Medicaid Services 
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Appendix Table B.2 Regression-adjusted estimates for the association between MRSAa SIRb 




Length of Stay 30-Day 
Mortality 
ICUc Days 
 b(SE) b(SE) b(SE) b(SE) 
MRSA SIR 0.011 0.007 0.006 32.488 
 (0.011) (0.005) (0.010) (52.013) 
CLABSId SIR -0.015 0.016* -0.002 52.247 
 (0.029) (0.007) (0.012) (78.150) 
CAUTIe SIR -0.008 -0.010 -0.002 -175.096* 
 (0.014) (0.005) (0.014) (79.117) 
Teaching 0.135* -0.020 0.057 733.218 
 (0.066) (0.030) (0.051) (520.306) 
Bed Count -0.000 0.001 -0.000 9.413*** 
 (0.000) (0.000) (0.000) (1.521) 
Quality Accredited 0.159 0.072* 0.061 325.229 
 (0.087) (0.033) (0.119) (225.754) 
Changes in 





























%ICU Beds 0.004 -0.012** -0.004 529.761*** 
 (0.004) (0.004) (0.004) (91.855) 
Patient Safety 
Indicator 
0.059 -0.037 0.239** -101.193 
 (0.051) (0.027) (0.070) (281.017) 
2014 -0.320*** 0.028** -0.320*** 207.554** 
 (0.042) (0.009) (0.014) (69.251) 
2015 0.014 0.031* 1.150*** 473.929*** 
 (0.051) (0.012) (0.027) (134.330) 
2016 -0.290*** 0.029 0.831*** 649.017*** 
 (0.056) (0.018) (0.037) (125.985) 
2017 -0.296*** 0.003 0.733*** 612.580*** 
 (0.056) (0.023) (0.040) (146.573) 
Constant 15.702*** 3.440*** 11.886*** 325.305 
 (0.213) (0.271) (0.294) (1417.925) 
N 8414 8258 8029 7850 
r2 0.095 0.022 0.630 0.139 
a Methicillin-resistant Staphylococcus aureus 
b Standardized infection ratio 
c Intensive Care Unit  
d Central Line-Associated Blood Stream Infection 
e Catheter-Associated Urinary Tract Infection 
f Centers for Medicare and Medicaid Services 
* p<0.05 ** p<0.01 *** p<0.001 
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Appendix Table B.3 Regression-adjusted estimates for the association between C.diffa SIRb 




Length of Stay 30-Day 
Mortality 
ICUc Days 
 b(SE) b(SE) b(SE) b(SE) 
C. diff SIR 0.023 0.025 0.038 39.028 
 (0.028) (0.013) (0.027) (125.787) 
CLABSId SIR -0.011 0.016* -0.001 40.642 
 (0.026) (0.007) (0.012) (63.861) 
CAUTIe SIR -0.010 -0.008 -0.001 -166.903* 
 (0.012) (0.005) (0.012) (73.356) 
Teaching 0.118* -0.006 0.042 648.886 
 (0.058) (0.029) (0.047) (465.339) 
Bed Count -0.000 0.001 -0.000 8.990*** 
 (0.000) (0.000) (0.000) (1.537) 
Quality Accredited 0.167 0.070* 0.073 301.393 
 (0.085) (0.033) (0.110) (213.688) 
Changes in 





























%ICU Beds 0.004 -0.011** -0.004 472.986*** 
 (0.003) (0.004) (0.005) (88.109) 
Patient Safety 
Indicator 
0.055 -0.039 0.228** -117.538 
 (0.049) (0.027) (0.065) (269.471) 
2014 -0.326*** 0.027** -0.322*** 198.390** 
 (0.041) (0.010) (0.013) (64.583) 
2015 0.010 0.027* 1.146*** 473.178*** 
 (0.050) (0.013) (0.026) (133.280) 
2016 -0.290*** 0.024 0.829*** 634.874*** 
 (0.053) (0.018) (0.036) (120.649) 
2017 -0.290*** 0.001 0.741*** 600.368*** 
 (0.052) (0.023) (0.037) (132.871) 
Constant 15.677*** 3.402*** 11.873*** 626.891 
 (0.203) (0.259) (0.292) (1364.925) 
N 9761 9576 9096 9086 
r2 0.093 0.021 0.627 0.127 
a Clostridioides difficile 
b Standardized infection ratios 
c Intensive Care Unit 
d Central Line-Associated Blood Stream Infection 
e Catheter-Associated Urinary Tract Infection 
f Centers for Medicare and Medicaid Services 
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